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6. ABSTRACT
This study investigated the extent to which insulin action and insulin secretion, 
measured using oral glucose tolerance tests (OGTT), euglycaemic hyperinsulinaemic 
clamp technique (clamp) and intravenous glucose tolerance tests (IVGTT), are 
controlled for by genetic factors among middle-aged non-diabetic twins (studies 
I to III). Then, a large population-based cohort of twins and a generation-long 
follow-up were used to assess the heritability (h2) for type 2 diabetes (T2D) (study 
IV). Finally, for the families participating in the Botnia Study, h2 was estimated for 
an array of metabolic traits associated with T2D (study V).
A subset of the older Finnish Twin Cohort Study participated in studies I to 
III, consisting of 151 twin pairs: 66 monozygotic (MZ; 28 female/38 male) and 85 
dizygotic (DZ; 33/52). In study IV, the complete older cohort was used, with 23,585 
twins in 4,076 MZ (1,911/2,165) and 9,109 DZ (4,570/4,539) pairs. In study V, the 
Botnia Study, information was obtained for 25,962 individuals from 1,131 families 
with at least one member with T2D. The current study was restricted to families 
with phenotype information from at least two members: 5,810 individuals (of which 
1,707 have T2D) in 942 families. The average family size was 6.17.
In studies I to III, all 151 pairs underwent an OGTT, while 42 pairs (22 MZ and 
20 DZ) took part in a 160-min euglycaemic hyperinsulinaemic (45 mU/m2min) 
clamp preceded by a 60-min IVGTT (Botnia clamp). In study IV, the twins’ self-
reported weight and height from 1975 were used to assess their baseline BMI. The 
T2D-incidence	data	was	collected	through	linking	records	from	death	certificates,	
the National Hospital Discharge and the Medication Registers between 1976 and 
1995. Use of the Medication Register was extended until 2004. In study V, all non-
diabetic individuals and those with T2D with fasting glucose less than 10 mmol·l–1 
underwent OGTT. Insulin sensitivity and secretion were assessed using the Botnia 
clamp. 
Insulin-stimulated glucose uptake (M-value) was measured from the last hour 
of clamp. Incremental insulin secretion was obtained using the trapezoidal rule 
for	 the	first	10	min	(first-phase	 insulin	–	FPI)	and	the	 last	50	min	(late-phase	
insulin – LPI) of IVGTT. In study II, a mathematical model used the IVGTT and 
OGTT	data	to	assess	the	first-	(readily	releasable	insulin	–	RRI)	and	second-phase	
(sigma) insulin secretion levels (IVGTT), as well as a global beta cell performance 
index (OGTT beta index). 
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For	studies	I	to	III,	the	intraclass-correlation	(IC)	coefficients	of	the	MZ	and	DZ	
pairs	were	first	compared.	In	study	II,	also	cross-twin	cross-trait	(ctct)	correlations	
(trait 1 of twin 1 vs. trait 2 of twin 2, and vice versa) were calculated by looking for 
common genetic factors between RRI and sigma. Maximum likelihood univariate 
analyses were used to estimate the additive (A), non-additive (D), shared (C) and 
unique (E) environmental components of variance for all traits of interest, using 
the Mx software. In studies III and IV, bivariate analyses were performed to study 
the latent genetic (rg) and environmental (re) correlations for fasting and 2-hour 
insulin values (III) and BMI and T2D (IV). In study V, the h2 values of T2D and 
anthropometric and metabolic traits were estimated using the SOLAR software.
In study IV, the hazard ratios (HRs) of incident T2D were calculated by 
categories, as integer values and as well per unit of BMI and per SD of BMI. Age-
adjusted bivariate genetic factor models were estimated separately for male and 
female twin pairs using the mean and variance weighted least-squares method. The 
bivariate model yielded, along with the variance components, phenotypic correlation 
coefficients	as	well	as	IC,	rg and re. 
In	study	I,	insulin	secretion	(IVGTT)	correlated	significantly	only	between	MZ	
twins, giving h2 = 0.55 for FPI and 0.58 for LPI. The clamp glucose uptake had 
only a modest MZ correlation (h2 = 0.37; p = 0.015).
In study II, the intraclass correlations (MZ/DZ) were 0.78/0.23 for RRI, 
0.67/0.32 for sigma and 0.57/0.42 for OGTT beta index. The h2 values were 0.76 for 
RRI, 0.28 for sigma and 0.53 for OGTT beta index. The ctct correlations between RRI 
and	sigma	were	non-significant,	indicating	that	they	represent	distinct	processes.
In study III, the h2 value of fasting insulin was 0.43. For 2-hour insulin h2 was 
0.51	in	female	twins,	whereas	in	male	twins,	no	significant	evidence	for	a	genetic	
effect was found. The genetic effects on fasting and 2-hour insulin levels were highly 
correlated (rg = 0.81).
In study IV, altogether 1,332 twins (6.3% of the men and 5.1% of the women) 
developed T2D. The HR for T2D increased with a mean of 1.22 (95% CI 1.20–
1.24) per BMI unit, 1.97 (95% CI 1.87– 2.08) per SD of BMI. The HRs for normal 
weight, overweight, obese and morbidly obese groups were 0.59, 2.96, 6.80 and 
13.64 compared with normal weight twins. The model-based h2 values for bivariate 
variance due to an additive genetic component and non-shared environmental 
component were 0.75 (men) and 0.71 (women) for BMI, and 0.73 and 0.64, 
respectively, for T2D. According to the bivariate model rg,	one	fifth	of	the	covariance	
of	BMI	and	T2D	was	due	to	shared	genetic	influences.	
In study V, the strongest heritability for T2D was among those aged 35–60 
years at onset (h2 = 0.69). Among quantitative traits, the highest h2 values for 
all individuals and non-diabetic individuals were seen for lean body mass (h2 = 
0.53–0.65), HDL-cholesterol (0.52–0.61) and suppression of NEFA during OGTT 
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(0.63–0.76), followed by measures of insulin secretion (insulinogenic index, IG30 
= 0.41–0.50) and insulin action (insulin sensitivity index, ISI = 0.37–0.40). Family 
means	of	these	traits	differed	two-	to	fivefold	between	families	belonging	to	the	
lowest and highest quartiles of the traits (p < 0.00001).
SUmmARy
1. Genetic factors explained most of the risk for type 2 diabetes mellitus. This 
conclusion	is	based	upon	the	finding	that	genes	accounted	for	as	much	as	64%	
of the T2D risk in female and 73% in male twins during a 28-year follow-up. The 
h2 of 69% for T2D among middle-aged Botnia Study family members was in line 
with the twin study. 
2.	The	variance	of	glucose-stimulated	insulin	secretion	included	a	significant	genetic	
component.	For	the	intravenously	stimulated	first	phase	of	 insulin	secretion,	h2 
varied between 58% and 76%. The h2 values of oral glucose-stimulated insulin 
secretion ranged from 46% to 53%. 
3. The h2 values of insulin-stimulated glucose disposal, insulin sensitivity, was 37% 
for the gold standard method, hyperinsulinaemic euglycaemic clamp. For surrogate 
techniques, the h2 values of insulin sensitivity varied between 37% and 42%. 
4. Genetic covariation with BMI explained 16% and 21% of the genetic covariance 
of T2D in men and women, respectively.
CONCLUSION
In the light of these twin and family studies, the majority of the risk for type 2 
diabetes mellitus is due to genes. While most of the heritability of T2D remains 
unexplained, the early phase of the pancreatic insulin secretion appears to be an 
aspect of metabolism that encompasses promising phenotypes for genomic studies.
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7. INTRODUCTION
The global prevalence of diabetes mellitus is surging and it was ranked as ninth in 
the	2010	report	on	the	global	burden	of	disease,	defined	as	years	lived	with	disability	
(YLD) (Vos 2012). The number of individuals with diabetes was approximated to 
be	118	million	in	1990	(Murray	1996).	Recent	predictions	suggest	that	this	figure	
will exceed 500 million by 2030 (Wild 2004, Shaw 2010) and in more than 9 out 
of 10 cases that will mean type 2 diabetes (WHO 2006). The expected relative 
increase in the prevalence varies between 20% and 100%, being highest in Africa, 
the Middle East and the eastern Mediterranean region (Shaw 2010). In Finland, 
the 2007 the number of incident cases of type 2 diabetes was 30 000 and there 
were 245 000 prevalent cases, respectively. The latter has been predicted to double 
every 12 years (Koski 2010). 
The diabetes epidemic is driven by urbanization, decreasing physical activity 
and	increasing	calorific	intake,	and	is	paralleled	by	the	obesity	pandemic.	Albeit	not	
evenly dispersed, the proportion of people who are overweight or obese is increasing 
in all continents. The rate is already high in European and North American countries, 
higher	in	the	Pacific	region	and	varies	more	among	African	and	Middle	Eastern	
countries (Prentice 2006). According to the WHO, since 1980 worldwide obesity 
has more than doubled (WHO 2013). In 2008, 1.5 billion adults aged 20 or older 
were overweight having a BMI over 25 kg·m–2. Of these, over 200 million men and 
nearly 300 million women were obese, i.e. their BMI was over 30 kg·m–2. In 2010, 
nearly	43	million	children	under	five	were	overweight.	In	Finland,	between	1978	
and 2010 the proportion of overweight adults increased from 42% to 58% among 
men, and from 37% to 50% among women (Helakorpi 2011).
Type 2 diabetes develops as a consequence of relative hypoinsulinaemia and 
insulin resistance of glucose metabolism in the liver and peripheral tissues, especially 
in skeletal muscle. The progress and changing views of the pathophysiology of 
type 2 diabetes is illustrated by two ADA award lectures from 1987 and 2008, by 
Ralph DeFronzo. In the Lilly Lecture 1987 (DeFronzo 1988), he nominated three 
disturbances, a “triumvirate”, as responsible for chronic hyperglycaemia: skeletal 
muscle insulin resistance and decreased glucose uptake, impaired insulin secretion 
by pancreatic beta cells and increased hepatic glucose production. In the Banting 
Lecture 2008, amid global escalation of both the type 2 diabetes pandemic and its 
research, the triumvirate had evolved to an octet (DeFronzo 2009). The additional 
five	members	 were:	 overproduction	 of	 glucagon	 from	 pancreatic	 alpha	 cells,	
decreased	influence	of	gut	incretin	hormones,	increased	lipolysis	in	adipose	tissue,	
increased glucose reabsorption in the kidneys and an impaired neurotransmitter 
function in the parts of the brain regulating glucose homeostasis. In addition to 
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these, at least impaired ability of subcutaneous adipose tissue to expand under a 
fuel	surfeit,	hyperadiponectinaemia	and	chronic	 inflammation	of	adipose	tissue	
have been suggested (Nolan 2011), suggesting defects in multiple pathways cause 
type 2 diabetes. 
Our	group	was	among	the	first	to	demonstrate,	that	healthy	first-degree	relatives	
of type 2 diabetes patients needed less external glucose to keep their plasma glucose 
normal during hyperinsulinaemia (Eriksson 1989). In other words, they were 
insulin resistant. The method used in the study, the hyperinsulinaemic euglycaemic 
clamp test, was and is still regarded as the gold standard for quantifying insulin 
sensitivity (DeFronzo 1979, Muniyappa 2008). Camilla Schalin-Jäntti from our 
group showed in 1992 that normoglycaemic but insulin-resistant relatives of type 
2 diabetes patients had impairment in the action of glycogen synthase in their 
skeletal	muscle	(Schalin-Jäntti	1992).	Taken	together,	these	findings	implied	that	
an inherited defect in skeletal muscle might render offspring of type 2 diabetes 
patients vulnerable to the same disease.
These	findings	set	in	motion	a	Finnish,	later	Finnish–Swedish,	effort	to	find	out	
which metabolic defects are inherited in families with type 2 diabetes. The Botnia 
Study	was	initiated	in	1990	in	four	Ostrobotnia	primary	health-care	units	(a	fifth	
was added in 1992). It collected data from all families with type 2 diabetes in the 
region (Groop 1996), and since then it has grown to become one of the leading 
projects in the world focusing on type 2 diabetes genetics (Demenais 2003).
At the same time as the onset of the Botnia Study, a population-based Finnish 
twin study on the cumulative incidence, concordance and heritability of both type 1 
and type 2 diabetes was conducted by Helsinki University (Kaprio 1992). The twins 
were	identified	using	the	Finnish	Twin	Cohort	Study,	which	is	a	national	resource	
for genetic epidemiological studies (Kaprio 1978, 1994). Somewhat unexpectedly, 
heritability for type 1 diabetes was found to be higher than for type 2 diabetes 
(Kaprio 1992). 
There were, thus, two differing results regarding the importance of genetic factors 
for	the	risk	of	type	2	diabetes.	Even	the	apparently	healthy	first-degree	relatives	
of the type 2 diabetes patients seemed to be insulin resistant, while a population-
based actuarial study showed only modest concordance between MZ twins. We 
hypothesized that by applying the classical twin study approach to non-diabetic 
subjects, who would undergo assessment of insulin sensitivity as measured with 
clamp, we could get an answer to the question: is insulin sensitivity an inherited 
trait? The preliminary discussions between the two research groups were successful 
and in addition to euglycaemic hyperinsulinaemic clamp, an intravenous glucose 
tolerance test was added to the protocol. The rationale was that type 2 diabetes 
manifests only when insulin secretion fails to overcome peripheral insulin resistance.
Both the Botnia and Twin Cohort studies throve. They yielded large amounts 
of information regarding type 2 diabetes and metabolic traits both within families 
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and during a long follow-up of more than 15 years. That was why the original study 
protocol including non-diabetic twin pairs was amended to estimate the heritability 
of metabolic traits within a large number of families with type 2 diabetes. In addition, 
as time had passed, there was an opportunity to return to the same twins used for 
the 1992 Diabetologia article, and re-estimate heritability for type 2 diabetes after 
a generation-long follow-up.
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8. REVIEW OF THE LITERATURE
8.1 TyPE 2 DIABETES mELLITUS AND RELATED mETABOLIC 
DISTURBANCES
8.1.1 OBESITy
Definition and diagnosis of obesity
The	World	Health	Organization	(WHO)	defines	overweight	and	obesity	as	abnormal	
or excessive fat accumulation that may impair health. They are caused by the energy 
imbalance between calories consumed and expended (WHO 2013). According to the 
Medical Subject Heading Browser (MeSH, http://www.nlm.nih.gov/mesh/2013/
mesh_browser/MBrowser.html ), obesity is “a status with body weight that is grossly 
above the acceptable or desirable weight, usually due to accumulation of excess fats 
in the body. The standards may vary with age, sex, genetic or cultural background.” 
The word “obesity” comes from the Latin expressions ob, meaning “against” or 
“over”, and edere, “to eat” (Waife 1955). 
Assessment of obesity
The assessment of obesity extends from an estimation of ponderosity to an estimation 
of the amount and distribution of bodily fat tissue. These may include: (1) comparing 
measured weight with the population average or a desirable weight obtained from 
respective weight tables, (2) calculating indices based on height and weight, (3) 
quantifying the amount of subcutaneous fat, (4) estimating whole body fat mass 
with a variety of techniques, (5) estimating the proportion of intra-abdominal fat 
either indirectly by measuring waist or waist and hip circumferences or directly 
with the use of X-ray or magnetic resonance imaging techniques (Lehtovirta 1973, 
Kissebah 1982, Ashwell 1985, Franssila-Kallunki 1992, Ross 1992, Browning 2010). 
Belgian mathematician and polymath Adolphe Quetelet developed the best-
known measure of obesity (Eknoyan 2008). In his 1835 published book entitled 
A Treatise of Man and the development of his faculties (English translation: 
Quetelet 1842), Quetelet showed, that other than growth spurts after birth and 
during puberty, weight of an average man increases as the square of the height 
(Quetelet 1842, Eknoyan 2008). The epidemiological validity of the Quetelet 
Index,	or	ponderal	 index,	was	first	confirmed	in	the	Framingham	study	(Florey	
1970), and renamed as Body Mass Index, BMI, by epidemiologist Ancel Keys (Keys 
1972).	Although	the	specificity	of	BMI	to	detect	people	with	excess	adiposity	 is	
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high, it is not a sensitive measure: as many as every other individual with normal 
BMI may yet have excess adiposity (Okorodudu 2010). However, because of its 
affordability and universal availability, BMI has maintained the position as the gold 
standard	in	the	classification	of	adiposity	among	adults	(Table	2)	(WHO	2000). 
Table 2. World Health Organization criteria for the classification of body mass index in adults.
Classification BMI (kg·m–2)
Principal cut-off points Additional cut-off points
Underweight < 18.50 < 18.50
Normal range 18.50–24.99
18.50–22.99
23.00–24.99
Overweight ≥ 25.00 ≥ 25.00
 Pre-obese 25.00–29.99
25.00–27.49
27.50–29.99
 Obese ≥ 30.00 ≥ 30.00
  Obese class I 30.00–34.99
30.00–32.49
32.50–34.99
  Obese class II 35.00–39.99
35.00–37.49
37.50–39.99
  Obese class III ≥ 40.00 ≥ 40.00
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Figure 1. Distribution of differences in weight of identical and fraternal twins and siblings (Newman 
1937). With permission of the University of Chicago Press.
Although Sir Francis Galton described the familial clustering of stature and collected 
a large dataset of anthropometric measures including weight, he did not differentiate 
“nature	from	nurture”	(Galton	1889).	Several	researchers	confirmed	the	resemblance	
of weight between family members some decades later (Davenport 1923). In the 
twin study by Newman et al., a striking similarity of weights of identical twin pair 
members was observed, compared to those among fraternal twin pairs and sibling 
pairs. The authors concluded that the difference must be due to genetic factors and 
that environmental factors are more important in the variability of weight than for 
height (Newman 1937). The contribution of genetic factors to weight, and weight 
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gain,	were	confirmed	by	MZ	overfeeding	studies	(Bouchard	1990)	and	studies	of	
twins reared apart (Stunkard 1990). According to population-based follow-up data 
from the Finnish Twin Cohort Study, the h2 values of baseline BMI were 0.80 in 
male twins and 0.82 in female twins and the h2 values for the rate of change of 
BMI from early adulthood to middle age were 0.58 and 0.64, while the respective 
genetic correlations between baseline and the rate of change were only -0.07 and 
0.04 (Hjelmborg 2008). 
Monogenic and syndromic forms of obesity are rare (Bell 2005) and 
the preponderant inheritance mode for obesity seems to be associated with 
polymorphisms in multiple genes (Cheung 2012). James Neel proposed in his 
“thrifty genotype” hypothesis in 1962 that genes and gene combinations, selected 
in the ancient environment of scarcity, have been rendered detrimental in modern 
environments where plenty of food is available without disruption (Neel 1962). Other 
obesogenic	genotypes	include	those	influencing	satiety,	levels	of	physical	activity,	
lipid oxidation and adipogenesis (Bouchard 2007). It is, however, the environment 
that provides the major stimulus for the globally observed increase in overweight 
and obesity. 
The latest version of the Human Obesity Gene Map from 2005 reports 176 
individual cases of obesity caused by a single gene defect and 253 QTLs from 61 
genome-wide location studies, including 52 regions supported in more than two 
studies (Rankinen 2006). Since then, genome-wide association studies (GWASs) 
have provided at least 52 new obesity-associated trait gene regions (Loos 2012), the 
most promising among them being the fat mass and obesity gene (FTO) (Frayling 
2007) and a locus near the melanocortin 4 receptor (M4CR) gene (Farooqi 2003, 
Chambers 2008). Despite the abundance of obesity-related gene regions, their 
combined contribution to the trait variance was found to be less than 5% in 2010 
(Speliotes 2010). One of the most recent genome-wide complex trait analyses 
(GCTAs) estimated that common variant heritability of BMI is 20% (Visscher 2012).
8.1.2. TyPE 2 DIABETES mELLITUS 
Definition and diagnosis of type 2 diabetes
Type 2 diabetes mellitus and intermediate forms of hyperglycaemia lie on a 
continuum of metabolic disturbances where blood (plasma) glucose concentration 
exceeds the normal range either in the postprandial or fasting state or in both 
states (WHO 2006). The current WHO threshold values for diagnosing diabetes, 
impaired glucose tolerance (IGT) and impaired fasting glycaemia (IFG) are shown 
in Table 3 (WHO 2006).
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Table 3. Threshold values for diagnosing diabetes, impaired glucose tolerance (IGT) and impaired 
fasting glycaemia (IFG) according to the World Health Organization’s 2006 criteria.
Value Diabetes Impaired glucose tolerance (IGT)
Impaired fasting 
glycaemia (IFG)
Fasting plasma 
glucose
≥7.0 mmol·l–1  
(126 mg·dl–1)
<7.0 mmol·l–1  
(126 mg·dl–1)
6.1–6.9 mmol·l–1 
(110–125 mg·dl–1)
or and and, if measured
2-hour plasma 
glucose*
≥11.1 mmol·l–1  
(200 mg·dl–1)
≥7.8 mmol·l–1  
(140 mg·dl–1) and <11.1 
mmol·l–1 (200 mg·dl–1)
<7.8 mmol·l–1  
(140 mg·dl–1)
Random glucose
≥11.1 mmol·l–1  
(200 mg·dl–1) with 
classic symptoms
HbA1C ≥6.5%
* 2-hour plasma glucose is the venous plasma glucose level 2 hours after ingestion of 75 g oral 
glucose load. If it cannot be measured, the diabetic status is rendered unclear as diabetes or IGT 
cannot be excluded.
Epidemiology of type 2 diabetes
Type 2 diabetes seems to cluster in families regardless of ethnicity (Knowler 1981, 
Köbberling 1982, Gardner 1984, Shaten 1993, Mitchell 1993, Lee 1995, Bjørnholt 
2000, Meigs 2000, Sargeant 2000, Erasmus 2001). A family history of type 2 
diabetes has been associated with defects in insulin action, insulin secretion or 
both (Lillioja 1987, Eriksson 1989, Vauhkonen 1998). The sibling relative risk of 
type 2 diabetes, compared to the risk for the background population, is around 3 
(Lyssenko 2005). Having one parent with type 2 diabetes increases the lifetime 
risk for an offspring for the same disease by 40%. If both parents are affected, then 
the offspring risk for diabetes is 70% (Köbberling 1982, Groop 1996). Twin studies 
have	provided	support	for	the	hypothesis	that	there	are	genetic	influences	on	type	
2 diabetes, both from the higher concordance rates in MZ than in DZ twins and 
from	the	significant	h2 estimates (Then Berg 1938, Harvald 1963, Gottlieb 1968, 
Pollin 1969, Tattersall 1972, Pyke 1976, 1978, 1979, Barnett 1981a, 1981b, Köbberling 
1982, Newman 1987, Anon 1988, Kaprio 1992, Matsuda 1994, Medici 1999, Poulsen 
1999). Using population-based Finnish twin data, the h2 for type 2 diabetes was 
calculated as 79% (Kaprio 1992).
Genetics of type 2 diabetes
Although it is axiomatic that environmental factors drive diabetogenesis, it is as 
evident that major differences exist in the individual responses to fuel surfeit. 
These differences have genetic origins. Understanding the genetics of type 2 
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diabetes has increased through technological innovation. The candidate gene 
approach is based on a known function of a gene for a trait and on the search 
for the association of these gene variants with the trait in the study population. 
Genes for peroxisome proliferator-activated receptor gamma (PPARG) (Deeb 
1998), potassium inwardly-rectifying channel, subfamily J, member 11 (KCNJ11) 
(Hani 1998), insulin receptor substrate-1 (IRS1) (Almind 1993), hepatocyte 
nuclear factor 1 homeobox B (HNF1B) (Winckler 2005) and Wolfram syndrome 
1 (wolframin, WFS1) (Minton 2002) are the few type 2 diabetes genes that have 
been found by identifying candidate genes. An earlier approach was linkage 
analysis, which used 400–500 markers covering the entire genome. The search 
for	linkages	using	data	from	affected	families	identified	two	genes:	calpain	10	
and transcription factor 7-like 2 (Hanis 1996, Grant 2006). 
The	identification	of	single-nucleotide	polymorphism	(SNP)	variations	enabled	
simultaneous genotyping of hundreds of thousands of SNPs. This, especially via the 
International Haplotype Map Project, HapMap (International HapMap Consortium 
2005), paved the way for genome-wide association studies of type 2 diabetes, several 
of which were published between 2007 and 2009. These were followed by three large 
meta-analyses, which combined information from several GWASs and extended SNP 
coverage (Saxena 2007, Scott 2007, Zeggini 2007, Sladek 2007, Steinthorsdottir 
2007, The Wellcome Trust Case Consortium 2007, Unoki 2008, Yasuda 2008, Tsai 
2010, Kong 2009, Jonsson 2009, Zeggini 2008, Qi 2010, Dupuis 2010). 
At	present	more	than	65	type	2	diabetes	gene	loci	have	been	identified.	More	than	
half	are	associated	with	beta	cell	function	and	insulin	secretion,	five	are	associated	
with insulin sensitivity and one, the fat mass and obesity (FTO) gene, with BMI 
(Dina 2007, Frayling 2007). Most rare monogenic forms of type 2 diabetes seem 
to result from defects in insulin secretion (Murphy 2008). Despite the impressive 
number of loci found, they are estimated to explain only 10–15% of the total variance 
of type 2 diabetes. The rest, sometimes called the “genetic dark matter” or “missing 
heritability”, is assumed to consist of rare (low frequency) genetic variants, gene–
gene interactions and epigenetic phenomena (Sparsø 2009; Simmons 2007).
8.1.3 INSULIN SECRETION
Insulin was originally discovered in 1921 and named pancreine by Nicolae Paulescu, 
a Romanian physician. However, the published work of the Canadians George 
Banting and Charles Best led to the recognition of insulin as a treatment for diabetes 
in 1922 (Banting 1922). For this, Banting and his supervisor John Macleod received 
the	Nobel	Prize	for	physiology	or	medicine	 in	1923.	James	Collip,	who	purified	
the insulin extract, was nominated years later (1935) and Best as late as 1950 (de 
Leiva-Pérez 2010). Measuring insulin secretion and insulin sensitivity were not 
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possible until the development of the radioimmunoassay of insulin by Rosalyn 
Yalow and Solomon Berson in 1960 (Yalow 1960), another discovery awarded the 
Nobel Prize (Kahn 2004).
Physiology of insulin secretion
Insulin is a small 51-amino acid polypeptide hormone, which has a major role 
in the regulation of glucose metabolism, directly by suppressing endogenous 
glucose production and indirectly by suppressing glucagon secretion and lipolysis. 
Native insulin is a globular protein with a zinc-coordinated hexamer. Each insulin 
monomer contains two chains, A (21 residues) and B (30 residues), linked by 
two disulphide bonds (Conlon 2001). The precursor protein of insulin, proinsulin 
(Steiner 1967), is formed in the rough endoplasmic reticulum of beta cells, and 
then it moves to the Golgi region, where its enzymatic cleavage to insulin and 
C-peptide is initiated (Steiner 1969). Insulin and C-peptide are stored in storage 
granules in equimolar amounts, and secreted to the circulation in an active 
exocytotic process (Steiner 2004). When nutrients evoke insulin secretion, the 
beta	cell	response	is	biphasic	(Curry	1968).	The	first	phase	can	also	be	triggered	
by other, non-metabolizable stimuli (Rorsman 2003). It is assumed that the 
slower second phase is energy dependent. Less than 5% of insulin-containing 
exocytotic granules constitute a readily releasable pool, which can be mobilized 
immediately	(Rorsman	2000).	The	first	phase	has	been	shown	to	undergo	a	
selective loss before type 2 diabetes ensues (Ward 1984). 
The oscillatory manner of insulin secretion was detected in the late 1970s 
(Goodner 1977, Lang 1979) and was explained by the existence of a “pancreatic 
pacemaker” (Lang 1981). Kenneth Polonsky, by deconvoluting peripheral 
C-peptide concentrations, demonstrated that both 8–15 min as well as ultradian 
(1.5–2 h) oscillations are present (Polonsky 1988). The former persisted despite 
deterioration of glucose homeostasis while both the temporal and amplitude 
characteristics of the latter changed during the transition from normal glucose 
tolerance to type 2 diabetes (Polonsky 1995). Today it is assumed that delivery of 
portal insulin from the pancreas occurs with a steady interval of approximately 
5 min between bursts. The amplitude and, hence, the mass of insulin in each 
burst varies depending upon the secretory stimuli (Meier 2005). Recent research 
suggests that the pulsatile secretion results from two superimposing oscillations 
in the beta cells: metabolically controlled ones, less dependent on plasma glucose 
concentration, as well as fast ones, which affect the amount of insulin in the 
bursts (Bertram 2007). Matveyenko demonstrated for dogs and rats that hepatic 
insulin resistance, an early defect in diabetes, follows a deterioration in timing 
of the pancreatic insulin bursts (Matveyenko 2012).
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In addition to impaired beta cell function, cumulating evidence supports the role of 
diminished beta cell mass in the pathogenesis of type 2 diabetes (Butler 2003, Kahn 
2008) although reliable methods to assess both beta cell function and mass are not 
yet available (Kahn 2008); therefore most results for impaired beta cell function and 
reduced beta cell mass in type 2 diabetes are not conclusive (Rahier 2008).
Genetics of insulin secretion
The	first	studies	of	insulin	secretion	to	use	twins	were	Scandinavian.	Erol	Cerasi	and	
Rolf Luft from Sweden studied diabetes discordant MZ twin pairs using intravenous 
glucose infusions (Cerasi 1967) and concluded in 1967 that a “low insulin response” 
indicated an increased genetic risk for diabetes. Allan Vaag et al. from Denmark 
confirmed	the	findings	by	applying	both	euglycaemic	and	hyperglycaemic	clamps	to	
MZ twins discordant for type 2 diabetes in 1995 (Vaag 1995). Our group (Eriksson 
1989)	was	 among	 the	first	 (O’Rahilly	 1986,	Bogardus	 1989,	Pimenta	 1995)	 to	
illustrate the same among non-diabetic family members of individuals with type 
2	diabetes.	Steven	Elbein	et	al.	obtained	the	first	estimate	for	insulin	secretion	h2 
values as late as 1999. They studied 120 individuals from sibships where at least one 
sib had type 2 diabetes. The h2 values for the acute insulin response to intravenous 
glucose was 38% in all and 33% in normoglycaemic subjects, and 67% and 70% 
when insulin sensitivity was accounted for, respectively (Elbein 1999). The lack of 
population-based h2 values for insulin secretion motivated us to perform the studies 
included in the current thesis.
The	first	 few	years	of	GWASs	almost	quadrupled	the	number	of	genetic	 loci	
associated with type 2 diabetes (Sparsø 2009) and most novel loci were involved in 
beta	cell	function.	Schäfer	et	al.	classified	the	loci	into	those	affecting:	(1)	glucose-
stimulated insulin secretion, (2) proinsulin to insulin conversion and (3) incretin 
secretion or incretin sensitivity (Schäfer 2011). One of the main type 2 diabetes risk 
genes, TCF7L2, interferes with all three mechanisms (Lyssenko 2007).
In general, the study of the genetics of insulin secretion is and will be dependent 
on	how	precisely	the	respective	phenotype	can	be	defined.	Accordingly,	diabetes	
risk estimation is and will be based upon clinical criteria, not upon individual risk 
genotypes (Herder 2011).
Assessment of insulin secretion
Measuring insulin secretion from plasma insulin concentrations involves a 
compromise:	50–80%	of	the	secreted	insulin	is	extracted	during	the	hepatic	first	pass,	
which also attenuates the amplitude of the insulin secretory bursts by a factor of 100 
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(Polonsky 1995, Meier 2005). Furthermore, insulin clearance decreases in response 
to hyperglycaemia (Byrne 1995). In addition, both the variability of insulin assays as 
well as the satiability of the whole body insulin clearance must be taken into account 
in the reconstruction of the actual secretory pattern of beta cells (Camastra 2007). 
Basal insulin secretion is usually estimated from samples of plasma taken after 
an overnight fast of 10 to 12 hours. Tests of stimulated insulin secretion are based 
on	introducing	a	finite	amount	of	glucose	or	a	secretagogue,	either	intravenously	
or orally, and sampling plasma to estimate insulin or C-peptide concentrations. 
The interpretation of the results using oral glucose loads differs from that of using 
intravenous glucose because orally administered nutrients stimulate the secretion 
of several gastrointestinal peptides, incretin hormones like GLP-1 and GIP, which 
further stimulate insulin secretion during a meal and modulate pancreatic glucagon 
responses (Rask 2004). 
In the following, I have compiled a description of the methods used to assess 
insulin secretion. Because the minimal model and C-peptide kinetics constitute a 
central theme in the study of beta cell function in vivo, they are in a separate section.
Fasting values and indices
Fasting insulin concentration
Although often used to mean the basal insulin secretion, the fasting plasma insulin 
concentration	reflects	both	insulin	secretion	between	meals	as	well	as	the	insulin	
sensitivity of glucose metabolism, and thus is merely a proxy for insulin resistance 
and basal insulin clearance (Ferrannini 2003). This, of course, has not prevented 
researchers from using it and its derivatives as measures for beta cell function 
(Bille 2011). 
Homeostasis model assessment of insulin secretion: the HOMA-BETA 
index
The assumption that the pancreas and liver function using a negative feedback 
loop led Robert Turner et al. to model an interaction where fasting glucose and 
insulin	concentrations	reflect	both	the	degree	of	beta	cell	deficiency	and	insulin	
resistance (Turner 1979). While the most cited outcome of the work by Matthews 
has been the insulin resistance index, HOMA-IR (Matthews 1985), the work also 
yielded the basis for the beta cell index known as HOMA-BETA. It quantitates 
the percentage of beta cell capacity of an individual compared to that of an “ideal 
individual” younger than 35 years with maximal beta cell capacity. The calculation 
of the HOMA-BETA index is simple:
HOMA-BETA = 20 ∙ insulin ÷ (glucose − 3.5)  (Equation 1) 
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It	is,	however,	difficult	to	interpret	beta	cell	function	without	a	secretory	stimulus.	
We,	among	others,	have	shown	that	HOMA-BETA	 is	a	poor	predictor	of	first-
phase insulin secretion (Tripathy 2004). Festa et al. concluded that HOMA-BETA 
has practically no value in detecting beta cell secretory defects in individuals with 
impaired glucose metabolism (Festa 2008).
Non-steady-state methods
When administered orally, glucose and nutrients evoke an integrated pancreatic 
response due both to an increase of plasma glucose and to activation of the entero-
insular axis, i.e. the incretin system (McIntyre 1965, Diab 2010). In epidemiological 
studies, oral tests have been favoured because of their simplicity and affordability. 
In a clinical setting, a standard 2-hour OGTT is regarded as the gold standard 
method for the clinical diagnosis of type 2 diabetes.
Oral glucose tolerance test (OGTT)
In the oral glucose tolerance test, blood samples are taken before and at least 2 hours 
after ingestion of 75 g glucose. These are used in diabetes clinics to characterize 
individual glucose tolerance status and as a research tool to assess insulin secretion 
and insulin sensitivity simultaneously.
The glucose dose has varied between 50 g and 100 g, and has been assessed as 
1 g per kg weight (Svensgaard 1931, WHO 1965). The current standard regimen 
requires fasting and the administration of 75 g dextrose in 250–350 ml solution. 
Glucose levels are measured at least 2 hours later. This was recommended by the 
WHO in 1980 (WHO 1980). Insulin concentrations were measured in OGTT as 
soon as this became possible, but they have only been used for research. During 
the GWAS era, a need for more detailed metabolic phenotypes increased interest in 
insulin sensitivity indices. The utility of the vast epidemiological OGTT databases 
has, therefore, also increased.
In practice: After fasting glucose and insulin samples have been drawn, 75 g of 
glucose in 250–350 ml solution is ingested. Venous blood is sampled at 30, 60, 90 
and 120 min later to determine plasma glucose, insulin and/or C-peptide levels. 
The timing of ingestion has been shown to affect entero-insular responses and the 
glucose disappearance rate (Heine 1983); however, no detailed OGTT instructions 
have been made available. In clinical use, the most prevalent protocol includes 
samples only at the baseline and after 120 min. Extended OGTTs may include taking 
multiple samples during 240–300 min (Cobelli 2007). Instead of insulin, C-peptide 
concentrations have been increasingly used to estimate beta cell function, especially 
when diabetic patients are studied (Toyota 1977, Eaton 1980, van Cauter 1992).
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OGTT-derived insulin secretion indices
Insulin area under OGTT curve (0–120 min)
With the OGTT type of data with repeated measures where both the magnitude and 
the	distance	from	a	neighbouring	value	define	each	data	point,	it	is	feasible	to	use	
the area under the curve (AUC) to summarize the information (Fekedulegn 2007). 
Most researchers use the trapezoidal method for this (Yeh 1978). The commonest 
way to quantitate insulin secretion has been to calculate the incremental AUC (AUCI), 
which takes into account the increase of insulin concentration above the fasting 
level. The equation for this is:
AUCI = ��
12 ⋅ �𝑚𝑚(𝑖𝑖+1) +𝑚𝑚𝑖𝑖� ∙ 𝑡𝑡𝑖𝑖𝑛𝑛−1
𝑖𝑖=1
� − �𝑚𝑚𝑖𝑖 ⋅ � 𝑡𝑡𝑖𝑖
𝑛𝑛−1
𝑖𝑖=1
�  (Equation 2)
where ti is the individual time distance between measurements, mi is the individual 
measurement and n is the total number of measures. 
One of the limitations of AUCI is that it may yield negative values. Some authors 
set negative areas to zero and report only positive AUCI values but this introduces a 
bias into the variability of the data (Le Floch 1990). Fekedulegn et al. recommend 
that the biological characteristics of the trait in question should determine the 
most optimal measures (Fekedulegn, 2007). This implies, for instance, that the 
secretory dynamics of the hormone should be taken into account: in addition to 
AUCI, the maximal concentration, average concentration and the time from stimulus 
to maximal concentration may characterize the trait.
Insulinogenic index (IG30 or IG30)
Originally introduced in 1959 by Holbrooke Seltzer and Walter Smith, the 
insulinogenic	index	was	defined	as	the	1-hour	incremental	insulin	level	divided	by	
the incremental glucose concentration after ingestion of 100 g of glucose (Seltzer 
1959).	The	purpose	was	to	define	the	insulin	secretion	capacity	in	subjects	whose	
glucose tolerance varied from healthy to overt diabetes. The most common version 
of the insulinogenic index is the ratio of the incremental increase of insulin and 
glucose	levels	during	the	first	30	min	of	OGTT	(Phillips	1994):
∆𝐼𝐼𝐼𝐼𝐼𝐼30′
∆𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺30′  (Equation 3) 
The insulinogenic index was originally calculated using either the OGTT or the 
IVGTT (Seltzer 1967, Cerasi 1975) but currently OGTT is preferred (Tripathy 2004). 
36
LEHTOVIRTA – Heritability of Type 2 Diabetes and Related Traits
Intravenous glucose tolerance test (IVGTT)
The intravenous glucose tolerance test uses a single intravenous bolus of glucose after 
which plasma samples are collected to reconstruct the pancreatic insulin secretory 
response elicited by the bolus.
In practice: A simple modern version of IVGTT consists of a short intravenous 
infusion of 50% glucose with a dose of 0.3 g·kg–1. Samples for plasma glucose and 
insulin are taken at 0, 2, 4, 6, 8, 10, 20, 30, 40, 50 and 60 min later (Tripathy 
2003). The minimal model and FSIVGTT will be discussed later. 
Various numbers of blood samples have been used and variability also exists 
regarding the method. The glucose dose can be between 0.3 g·kg–1 and 0.5 g·kg–1 
(Bingley 1992), the maximal glucose dose between 25 g (Henriksen 2010) and 35 
g (Bingley 1992) and the concentration of glucose solution between 20% (Colman 
1992) and 50% (Smith 1988). The infusion time has varied between 1 min and 2 
min (Coates 1995). These factors tend to affect the early insulin response most 
(Colman 1992). 
As insulin secretion is related to glucose tolerance, a bolus of 0.5 U·kg–1 of short-
acting insulin (Coates 1995) or 300–500 g of tolbutamide (Beard 1986) has been 
given at 20 min, in some studies at 8 min (Valle 1998), to verify the maximal insulin 
effect on glucose removal. 
The current way to calculate insulin secretion from IVGTT is to calculate two 
incremental	insulin	areas:	an	early	(first)	phase	insulin	secretion,	calculated	as	the	
incremental insulin area between 0 min and 10 min after glucose infusion, and a 
late (second) phase, as the incremental insulin area between 10 min and 60 min 
after glucose infusion (Tripathy 2003). 
Graded glucose infusion
The graded glucose infusion technique and the hyperglycaemic clamp test (see 
below) are similar and differ mainly in the predetermination of the plasma glucose 
level in the latter and the use of C-peptide deconvolution in the former. 
Ken Polonsky et al. from the University of Chicago introduced the modern version 
of graded glucose infusion (Byrne 1995). Their work was based on pancreas perfusion 
experiments and studies of consecutive glucose boluses in “staircase”-like dosing by 
Gerold Grodsky (Grodsky 1972, Karam 1974). In Polonsky’s study, glucose infusions 
of 1, 2, 3, 4, 6 and 8 mg/kg weight, each lasting 40 min, were used and glucose and 
C-peptide concentrations measured every 10 min. Individual C-peptide kinetics 
were resolved and the insulin secretion rate estimated using a two-compartmental 
model (Byrne 1995). 
Other secretagogues
Glucagon was shown to be a useful insulin secretagogue in 1965 (Samols 1965). The 
6-min	glucagon	test	using	C-peptide	concentrations	to	reflect	beta	cell	function	was	
37
validated by Ole Faber and Christian Binder from Hvidovre Hospital in Denmark in 
1977 (Faber 1977). The test is mainly used to estimate the residual insulin secretion 
capacity in diabetic patients. The amino acid arginine on its own acts as a moderate 
stimulator of insulin secretion, but with glucose it is a potent stimulator of insulin 
secretion	(Gerich	1974).	It	was	first	used	to	study	insulin	and	glucagon	secretion	
(Palmer 1976) and later it was used to measure the maximal residual insulin 
secretory capacity (Ward 1984). Yalow demonstrated in 1960 that a potassium 
channel blocker, the sulphonylurea drug tolbutamide, was able to elicit a short but 
intensive burst of insulin from beta cells (Yalow 1960). Cerasi et al. later showed 
that the duration of the effect was dependent upon the glucose concentration (Cerasi 
1969).	Tolbutamide	is	currently	used	with	FSIVGTT	to	produce	a	sufficient	insulin	
peak to estimate glucose disappearance and insulin sensitivity (Beard 1986).
Steady-state methods: hyperglycaemic clamp
In a hyperglycaemic clamp test, a square wave of glucose infusion is used to increase 
plasma glucose to a chosen level in association with frequent sampling for insulin 
(DeFronzo 1979).
In practice: A variable 2-hour intravenous infusion of 20% glucose solution 
with a 15-min priming dose is administered to increase the venous plasma glucose 
concentration with to 6.9 mmol·l–1 (125 mg/dl in the original publication) (DeFronzo 
1979). The variable rate of the glucose maintenance infusion is computed every 5 
min taking into account both the glucose needed to cover the amount of glucose 
metabolized as well as the amount needed to account for the concentration change 
in the total glucose distribution space.
The simplest way to measure insulin secretion during a hyperglycaemic clamp 
test is to use the glucose-corrected insulin AUCI or, alternatively, the sum of the 
insulin	concentrations	from	the	first	10	min	(first-phase	insulin	secretion)	and	the	
glucose-corrected incremental mean insulin concentration from the last 60 min 
(second-phase insulin secretion) (Mitrakou 1992). A minimal model approach can 
also be used with hyperglycaemic clamp insulin and/or C-peptide data (Weiss 2005).
Minimal model and approaches to insulin secretion using C-peptide 
kinetics
The reason for the extensive review of minimal model and C-peptide kinetics 
here is twofold. First, we used an adjusted minimal model in study II. Second, 
while the euglycaemic clamp is the gold standard for measuring glucose uptake, 
the minimal model has been widely used to study insulin secretion using both 
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OGTTs and IVGTTs. The following includes both an introduction to estimating 
insulin secretion according to the original publication (Bergman 1981) as well as a 
short review of minimal models applied to C-peptide kinetics. The minimal model 
assessment of insulin sensitivity is presented in section Insulin action.
Richard	Bergman,	Claudio	Cobelli	et	al.	fitted	variable	compartmental	models	to	
FSIVGTT glucose and insulin data and chose a non-linear model, which included 
the hepatic glucose input and output, for the glucose kinetics (Bergman 1979) and 
a model with two separate pancreatic responses to glucose for the insulin secretion 
(Bergman 1981). After the implementation of C-peptide kinetics, the minimal model 
has been widely used to study beta cell function under different in vivo settings. It can 
be used with IVGTT, OGTT and meal tests as well as to hyperglycaemic clamp tests. 
In FSIVGTT, a 60-sec intravenous infusion of 50% glucose at a dose of 0.3 g·kg–1 
is administered. Blood samples are collected at 0, 2, 4, 6, 8, 10, 12, 14, 16, 19, 22, 
27, 32, 42, 52, 62, 72, 82, 92, 102, 122, 42, 162 and 182 min to estimate plasma 
glucose, insulin and/or C-peptide levels (Bergman 1981). 
Minimal model of insulin secretion 
Analogously with non-modelled approaches to IVGTT and hyperglycaemic clamp 
testing, in the minimal model the pancreatic response after a glucose bolus is divided 
into	 two	 components.	These	 are	 called	 the	first-	 and	 second-phase	pancreatic	
sensitivity, or responsiveness, to glucose: ϕ1 and ϕ2 (Toffolo 1980), respectively. 
The term ϕ1 represents the (rapid) release of insulin from beta cells in response to 
the glucose bolus and can be expressed with the equation:
𝜙𝜙1 =  𝐼𝐼𝑜𝑜𝑛𝑛 ⋅  𝛥𝛥𝛥𝛥  (Equation 4)
Io is the incremental value of the peak plasma insulin concentration following glucose 
administration, n	is	a	time	constant	for	insulin	disappearance	and	ΔG	is	the	maximal	
incremental glucose concentration increase. In other words, ϕ1 is the incremental 
maximal insulin concentration corrected for the incremental glucose concentration. 
The second-phase pancreatic sensitivity to glucose (ϕ2) is calculated as:
𝜙𝜙2 =  𝛾𝛾(𝐺𝐺(𝑡𝑡) − ℎ) ⋅ 𝑡𝑡 –𝑛𝑛 ⋅ 𝐼𝐼(𝑡𝑡) (Equation 5)
In	the	equation,	γ	is	the	glucose	sensitivity	of	beta	cell	response,	G(t) is the glucose 
concentration at each time moment (t), h is a glucose threshold for the beta cells 
response and I(t) is the plasma insulin concentration at each time moment.
There is no consensus about the terminology: Io has also been termed the “acute 
insulin response” (AIR) (Nittala 2006), and AIRg (AIR corrected for glucose) has 
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been used as a synonym for ϕ1. Several authors, furthermore, use these acronyms, 
AIR and AIRg, without using the minimal model but AUC calculations instead. 
As the relation between beta cell function and insulin sensitivity has been shown 
to be hyperbolic (Turner 1979), the authors tested the separate products of either ϕ1 
or ϕ2 and the minimal model insulin sensitivity index SI, and in the original study 
concluded that the latter, ϕ2⋅SI was the best single measure to separate glucose 
intolerant from glucose tolerant subjects (Bergman 1981). The product, known as 
the disposition factor or disposition index (DI), has been widely estimated using 
other measures for insulin sensitivity and secretion (Dorkhan 2008, Laakso 2008).
Insulin secretion using C-peptide concentrations
The inter-individual volatility of insulin disappearance can be circumvented by using 
C-peptide, which is co-secreted in an equimolar ratio with insulin. In 1980, R. Philip 
Eaton from the University of New Mexico assessed prehepatic insulin delivery using 
peripheral C-peptide concentrations and validated a two-compartment model for 
C-peptide concentrations (Figure 2) (Eaton 1980). Eaton’s work served as a starting 
point for all major OGTT C-peptide models, including our own (Cretti 2001, Breda 
2001, Mari 2002).
Fig 2
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Figure 2. Two-compartment C-peptide model. According to Eaton 1980.
The total intravascular C-peptide pool C is in dynamic equilibrium with the non-
accessible total extravascular C-peptide pool Y; S(t) is the production of C-peptide, 
i.e. the insulin secretion rate, and k1, k2 and k3 are fractional turnover rates. 
Mathematically, the time derivatives of the compartments are:
𝑑𝑑
𝑑𝑑𝑑𝑑
𝐶𝐶(𝑑𝑑) = −(𝑘𝑘1 + 𝑘𝑘3)𝐶𝐶(𝑑𝑑) + 𝑘𝑘2𝑌𝑌(𝑑𝑑) + 𝑆𝑆(𝑑𝑑)  (Equation 6)
𝑑𝑑
𝑑𝑑𝑑𝑑
𝑌𝑌(𝑑𝑑) = 𝑘𝑘1𝐶𝐶(𝑑𝑑)− 𝑘𝑘2𝑌𝑌(𝑑𝑑)  (Equation 7)
By combining the above equations and solving for S(t), a single equation describing 
C-peptide production can be obtained. While beyond the scope of this thesis, it 
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deserves to be noted that, thanks to Eve van Cauter et al., k1 – k3 can be satisfactorily 
estimated from sex, age, body surface area and information about diabetic status 
and obesity (van Cauter 1992).
The second basis of glucose/C-peptide models is the non-linear glucose minimal 
model including hepatic glucose extraction and output (Figure 3) (Bergman 1979). 
I(t)
k2 k3
k6
k5 k1
k4
I’
Liver PeripheryG
Fig 7
Figure 3. Glucose minimal model including hepatic glucose extraction. According to Bergman 1979.
The third component is the minimal model of insulin secretion (Figure 4) (Bergman 
1981). 
 
Insulin
distribution
space
Y(G-h)t –nI(t)
Fig 4
Figure 4. Minimal model of insulin secretion. According to Bergman 1981.
Different approaches have been taken to combine these three submodels. The robust 
rudiments of these approaches are shown in Figure 5, which displays the minimal 
model	of	glucose	and	C-peptide	(insulin)	kinetics.	The	glucose	kinetics	in	the	figure	
are shown in grey to highlight the beta cell model. When glucose or other nutrients 
are administered orally (*) both the delay and incretin effects must be taken into 
account.
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Figure 5. Minimal model of glucose and C-peptide (insulin) kinetics including both oral and intravenous 
administration routes for glucose. Glucose kinetics are shown in grey to highlight the beta cell model. 
Adapted from Eaton 1980, Bergman 1979, 1981, Cretti 2001, Breda 2001 and Mari 2002.
In	the	original,	as	well	as	in	our	model,	the	influence	of	glucose	on	beta	cells	(arrow	
1) is given by a linear term with a rate constant (γ or σ) and a threshold (h or θ) 
(Bergman 1981, Cretti 2001):
𝛾𝛾(𝐺𝐺(𝑡𝑡) − ℎ)  (Equation 8) 
The provision of new C-peptide (insulin) to be secreted (X) in response to the 
glucose stimulus (arrow 2) is
𝛾𝛾(𝐺𝐺(𝑡𝑡) − ℎ)− 𝑛𝑛𝑛𝑛(𝑡𝑡)  (Equation 9)
We have used τ–1 instead of n (Cretti 2001). The secretion rate, thus, has the same 
structure as the minimal model ϕ2 (see Equation 5 above). In our model, the 
basal C-peptide secretion rate (arrow 3) is estimated to be constant throughout 
the experiment and related to basal C-peptide concentration, its estimated volume 
of distribution and body surface area.
Cobelli et al. (Breda 2001) added a dynamic secretory component to the model. 
It is different from zero only if glucose concentration is between basal (Gb) and 
threshold (Gt) levels (where threshold Gt is different from threshold h). This adds 
the	first-phase	insulin	secretion	component	to	OGTT.	The	equation	for	the	dynamic	
secretory component according to these authors is: 
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𝑆𝑆𝑆𝑆𝐷𝐷 =  𝐾𝐾𝑑𝑑 ∙ �1 − 𝐺𝐺(𝑡𝑡) − 𝐺𝐺𝑏𝑏𝐺𝐺𝑡𝑡 − 𝐺𝐺𝑏𝑏 � ∙  ?̇?𝐺(𝑡𝑡)  (Equation 10) 
In this equation, Kd is a constant and Ġ(t)= 
 
𝑑𝑑𝑑𝑑(𝑡𝑡)
𝑑𝑑(𝑡𝑡)  . 
Mari	et	al.,	on	the	other	hand,	studied	24-hour	glucose	and	C-peptide	profiles	in	
people	under	free-living	conditions	(Mari	2001)	and	modelled	the	influence	of	the	
Staub–Traugott effect, which facilitates glucose disposal following closely spaced 
successive glucose loads (Staub 1921, Traugott 1922, Abraira 1978). As a result, the 
original	model	was	supplemented	with	a	“potentiation	factor”,	which	influences	the	
static secretory component. The mathematical form is: 
𝑆𝑆𝑔𝑔(𝑡𝑡) = 𝑒𝑒𝑄𝑄(𝑡𝑡)𝑓𝑓(𝐺𝐺)  (Equation 11)
In this equation, ݁ொሺ௧ሻ  is the potentiation factor, which varies around a mean value 
of 1, depending upon the term Q(t), which varies around zero in a piece-wise linear 
manner over 5 min intervals. Term f(G), representing the static secretory component, 
has a mathematical expression different from the previous ones (Cretti, Cobelli), but 
basically expresses a linear relation between glucose and C-peptide (Mari 2002).
An advantage of applying a minimal model to C-peptide (insulin) secretion 
is that the kinetic and secretion parameters can be solved despite physiological 
differences between OGTT and IVGTT. This has partly been due to the development 
of commercially available software designed for compartmental modelling: most of 
the referred studies have relied on SAAM software (Barrett 1998).
Measurement of pulsatile insulin secretion
In the original study in humans, Lang, Matthews, Turner et al. sampled peripheral 
plasma insulin every minute for one or two hours and detected frequent 13-min 
oscillations of plasma insulin with a mean amplitude of 1.6 mU/L (Lang 1979). 
Polonsky et al. used 28-hour constant or oscillatory glucose infusions with samples 
taken every 10 min to estimate glucose and C-peptide levels. The concentration 
values	were	 smoothed	using	software,	 followed	by	 identification	and	 temporal	
analysis of the pulse data (Polonsky 1988). Little progress regarding methodologies 
has been made since, and there is still no method for reliably and economically 
detecting and classifying the oscillatory patterns of C-peptide or insulin secretion in 
larger study samples. Recently, however, commercial software using deconvolution 
has been released, which can analyse the oscillatory patterns of fasting insulin 
concentrations. The sampling interval is 30 sec and a study can be performed in 
just 1 hour (Johnson 2010).
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8.1.4 INSULIN ACTION
Insulin has three major target organs. It decreases the hepatic output of glucose 
(both gluconeogenesis and glycogenolysis) (Bearn 1951, Craig 1961, Pilkis 1986) 
and it increases glucose uptake in skeletal muscle (Andres 1962) and adipose tissue 
(Rodbell 1964). 
Insulin increases lipid synthesis in liver and fat cells and suppresses the release 
of fatty acids from triglycerides both in muscle and fat cells. It suppresses protein 
breakdown in muscle, lipoprotein and triglyceride secretion in the liver and 
stimulates lipoprotein lipase activity in fat. Figure 6 summarizes the main targets 
of insulin action (Magkos 2010).
Figure 6. The main targets of insulin action (Magkos 2010). With permission from Elsevier.
Insulin	functions	by	binding	to	specific	receptors,	which	are	abundantly	located	on	
the cell surfaces of insulin-sensitive tissues. The extracellular paired alpha-subunits 
serve as binding sites, from where the signal is transferred to intracellular beta-
subunits, three tyrosine kinases of which are subsequently activated (White 1988). 
In skeletal muscle and in fat cells, the phosphorylation reactions following insulin 
binding to receptors activate several pathways.
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In the present study we have focused on the glucoregulatory effects of insulin, 
as measured using the euglycaemic hyperinsulinaemic clamp method.
Insulin sensitivity and insulin resistance
Insulin sensitivity and the lack of it, insulin resistance, are among the most studied 
and debated topics in medicine. Insulin resistance is not only the epicentre of the 
metabolic disorder type 2 diabetes mellitus but also precedes its onset. It is present 
in normoglycaemic relatives of patients with diabetes, characterizes the metabolic 
profile	of	multiple	other	disease	 states	and	 is	an	 independent	 risk	 factor	 for	a	
multitude of cardiovascular disorders as well as for certain cancers.
History of insulin resistance
Sir Harold P Himsworth from University College London studied healthy humans 
and published a series of pioneering articles about insulin action and insulin 
resistance in diabetes. In his most prominent work, published in 1936 in the Lancet, 
Himsworth discussed issues that are still at the core of insulin resistance research 
today. In addition to covering insulin action in peripheral tissues and the role of 
liver in insulin resistance, he also described a novel form of diabetes, the insulin-
insensitive type, currently known as type 2 diabetes mellitus, and estimated it to 
be more prevalent than the insulin-sensitive type of diabetes, i.e. type 1 diabetes 
(Himsworth 2011).
As late as 1970, insulin resistance was used to characterize diabetic patients 
needing large insulin doses. This was noted in the article by Shiao-Wei Shen, 
Gerald M. Reaven and John M. Farquhar from Stanford University, CA: “The word 
impedance is used as a synonym for hindrance, insensitivity, or resistance, but it 
is preferred to the latter to avoid confusion with the special use of resistance in 
diabetics who have acquired antibodies to exogenous insulin” (Shen 1970). The 
article, however, heralded the era of modern studies on insulin sensitivity. The 
term impedance did not become general and the insulin suppression test, although 
still used today (Liu 2013), lost out to other methods, mainly because of its limited 
usefulness among very insulin-sensitive and, on the other hand, highly insulin-
resistant subjects (Kim 2011). 
In an insulin suppression test, the normal insulin concentration is maintained 
with exogenous insulin and the resulting glucose concentration is measured. 
In the mid-1970s researchers from the NIH published two studies in which 
insulin infusion was used to generate hyperinsulinaemia and plasma glucose was 
maintained at normal levels with a variable glucose infusion (Sherwin 1974, Insel 
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1975). The primary aim of Sherwin, Insel, Andres, Tobin et al. was to describe the 
compartmentalization of insulin into pools with different equilibrium velocities. 
Their most eminent accomplishment was, however, that they developed the 
euglycaemic hyperinsulinaemic clamp technique (DeFronzo 1979). In addition to 
steady-state techniques like the clamp test, there are several methods where insulin 
sensitivity is estimated from non-steady-state data, the minimal model FSIVGTT 
being the best known (Bergman 1979).
The	 first	 association	 studies	 comparing	 fasting	 insulin	 concentration	 and	
anthropometric measures were published soon after Yalow and Berson had 
introduced the insulin RIA (Karam 1963). During the 1970s and 1980s several 
studies	 confirmed	 the	 association	 of	 fasting	 hyperinsulinaemia	 with	 insulin	
resistance, obesity, dyslipidaemia, impaired glucose tolerance and non-insulin-
dependent diabetes (Joffe 1975, Berglund 1976, Stout 1977, Pyörälä 1979, Garcia-
Webb 1983, Haffner 1986, Eriksson 1989). Terms like insulin resistance syndrome, 
metabolic syndrome, multimetabolic syndrome and syndrome X all referred to the 
clustering of risk factors for type 2 diabetes and cardiovascular diseases. These risk 
factors included dyslipidaemia, impaired insulin action on glucose metabolism, 
glucose intolerance, hyperinsulinaemia, obesity, central obesity and hypertension. 
The concept of insulin resistance was promoted in research meetings of the late 
1980s (DeFronzo 1988, Reaven 1988). Despite deviating views, for instance about 
insulin’s role as a cardiovascular risk factor (Jarrett 1992), by the early 1990s insulin 
resistance	had	been	solidified	as	one	of	the	central	concepts	of	modern	medicine.
Definition of insulin resistance
Insulin	resistance	is	not	a	disease,	merely	a	physiological	state.	Identification	of	
insulin resistance is important for the treatment of the disorders it glues together 
(Reaven 2005). Over the past 30 years, the list of disturbances associated with 
insulin resistance or included as components of insulin resistance syndrome has 
continuously	expanded	(Nolan	2011).	Different	classifications	of	insulin	resistance	
syndrome are shown in Table 4.
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Table 4. Varying criteria used for the definition of insulin resistance syndrome.
Trait WHO 1999 (Alberti 1998)
EGIR 1999
(Balkau 1999)
ATPIII 
(* 2001)
IDF 2005 
(Alberti 2005)
Type 2 diabetes Primary criterion Type 2 diabetes or 
fasting hyperglycaemia
Impaired glucose 
tolerance
Primary criterion
Insulin resistance or 
hyperinsulinaemia
Primary criterion Primary criterion
Fasting 
hyperglycaemia
Fasting plasma glucose 
≧ 6.1 mmol·l-1 
Fasting plasma glucose 
≧ 6.1 mmol·l-1 
Fasting plasma glucose 
≧ 5.6 mmol·l-1
Central obesity WHR > 0.9 M 
WHR > 0.85 F
Waist ≧ 94 cm M 
Waist ≧ 0.80 cm F
Waist ≧ 102 cm M 
Waist ≧ 0.88 cm F
Primary criterion with 
ethnic and gender 
specific cut points for 
waist
Obesity BMI2 > 30 kgm-2
Hypertriglyceridemia Triglycerides ≧ 1.7 
mmol·l-1 
Triglycerides > 2.0 
mmol·l-1
Triglycerides ≧ 1.7 
mmol·l-1 
Triglycerides ≧ 1.7 
mmol·l-1 or specific 
treatment
Low HDL cholesterol HDL ≦ 0.9 mmol·l-1 M 
HDL ≦ 1.0 mmol·l-1 F
HDL < 1.0 mmol·l-1 HDL < 1.03 
mmol·l-1 M 
HDL < 1.29  
mmol·l-1 F
HDL < 1.03 mmol·l-1 M
HDL < 1.29 mmol·l-1 F
or specific treatment
Hypertension BP ≧ 140/90 mmHg or 
medication
BP ≧ 140/90  
mmHg or medication
BP ≧ 135/85  
mmHg or medication
Systolic ≧ 130 mmHg or
Diastolic ≧ 85 mmHg or 
medication
Microalbuminuria Albumin excretion 
rate ≧ 20 µg·min-1 or 
albumin : creatine ratio 
≧ 30 mg·g-1 
Number of 
secondary criteria 
needed
Two or more Two or more Three or more Two or more
* Reference: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in 
Adults
Genetics of insulin resistance
When the current study was initiated, practically all published twin study h2 
estimates of insulin sensitivity or resistance were based on fasting insulin and 
glucose concentrations (Hong 1997, Narkiewicz 1997, Mayer 1996, Snieder 1999). 
The fasting insulin and glucose-based h2 estimates varied between 0.20 and 0.54. 
The heritability for insulin sensitivity among Pima Indian families using euglycaemic 
hyperinsulinaemic clamp tests ranged from 0.38 to 0.49, depending upon the level 
of hyperinsulinaemia (Sakul 1997). With FSIVGTT and the minimal model, the h2 
for the insulin sensitivity index (SI) was 0.38 for all, and 0.29 for family members 
with normal glucose tolerance among European sib pairs from families with type 
2 diabetes (Elbein 1999). Likewise, the h2 for SI
 among Finnish families with type 
2 diabetes was 0.28 (Watanabe 1999). 
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Until the development of DNA chip technology, only a couple of genes associated 
with	insulin	resistance	had	been	identified.	The	most	prominent,	and	practically	
the only one that was replicated by several independent research groups, was the 
peroxisome proliferator-associated receptor gamma gene, PPARG (Greene 1995), 
identified	by	us	using	a	parent–offspring	design	(Altshuler	2000).
Although	the	majority	of	new	loci	suggested	by	the	first	two	waves	of	GWASs	
were associated with insulin secretion, some interesting gene regions associated 
with insulin action were found as well. An allele of an SNP close to the ADAMTS9 
(a disintegrin and metalloproteinase with thrombospondin type 1 motif 9) gene, 
included in the DIAGRAM Consortium meta-analysis (Zeggini 2008), was shown 
to be associated with decreased insulin sensitivity of peripheral tissues (Boesgaard 
2009). The third and fourth waves of GWASs added to the list, among other genes, 
insulin receptor substrate 1 (IRS1) (Rung 2009, Sun 1991), glucokinase regulator 
(GCKR) (Dupuis 2010, Warner 1995) and glucokinase (GCK) (Dupuis 2010), which 
was originally linked to type 2 diabetes in 1992 (Hattersley 1992).
Assessment of insulin sensitivity or insulin resistance
The focus here is restricted to methods for quantitating insulin sensitivity or insulin 
resistance of glucose metabolism. In an excellent review of whole body glucose 
metabolism, Kenneth Zierler, developer of the forearm technique, subdivided 
glucose uptake estimation methods into those based on measurement of single organ 
input-output differences and those based on whole body steady-state estimations, 
and regarded the rest, including all compartmental models, as representations of 
“lumped” models (Zierler 1999). I chose, however, to classify insulin sensitivity 
assessment methods as: (1) fasting values and indices built around them, (2) non-
steady-state methods and (3) steady-state methods, where there is a progression 
in the requirements of the techniques.
In general, all estimations of insulin sensitivity are performed after an overnight 
(10–16 h) fast after the study subjects have been on a weight-maintaining diet for 3 
to 7 days. The basic weight-maintaining diet is expected to include at least 250 g, or 
5 g/kg weight, of carbohydrates. The most common macronutrient composition used 
before metabolic studies has been described as 50–60% carbohydrates, 20–30% 
fat and 15–20% protein.
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Fasting values and indices
Fasting insulin concentration
The	correlation	of	 fasting	 insulin	with	 insulin	sensitivity	was	0.58	among	first-
degree relatives of type 2 diabetes patients in the Botnia Study, Finland (Groop 
1996), 0.61 among healthy volunteers in Stanford, CA, USA (Yeni-Komshian 2000) 
and 0.81 among diet-treated type 2 diabetes patients in Oxford, UK (Matthews 
1985). Skeletal muscle insulin sensitivity, however, explains only part (at most 
30%) of the variance of fasting insulin levels. When insulin-stimulated glucose 
uptake and fasting insulin concentrations from 1,308 subjects in the EGIR 
(European Group for the study of Insulin Resistance) database were compared, 
the overlap of insulin resistance criteria using both methods was only 60% 
(Ferrannini	2002).	As	the	authors	wrote:	“The	explanation	for	this	finding	lies	in	
the fact that insulin resistance is only one of the determinants of FPI. Systemic 
plasma	insulin	concentrations	are	the	result	of	β-cell	release	and	plasma	removal	
of the hormone. Other known positive modulators of the fasting insulin secretory 
rate are the fasting plasma glucose concentration and the degree of obesity.” 
Homeostasis model assessment of insulin resistance, HOMA-IR 
(HOMA-R) index
By studying the relation between fasting plasma glucose and insulin concentrations 
in 65 newly diagnosed non-complicated diabetes patients, Robert Turner developed 
a single-compartment model based on a feedback loop between the liver and beta 
cells. The model can be used to estimate the degree of individual insulin resistance 
and	beta	cell	defect	(Turner	1979).	A	simplification	of	the	model,	HOMA-IR,	was	later	
shown	to	reflect	satisfactorily	insulin	resistance	measured	using	more	sophisticated	
methods, both among healthy and diabetic subjects (Matthews 1985). Due to the 
modest amount of sampling and analytics needed, HOMA indices became widely 
used in epidemiological and genetic studies. HOMA-IR is calculated from fasting 
plasma glucose and insulin concentrations as:  
HOMA-IR = insulin22.5 ∙ 𝑒𝑒− ln(glucose) =  insulin ∙ glucose22.5   (Equation 12)
There are two caveats with HOMA-IR. In the original work by Matthews, the HOMA-
IR equation was reserved for normal weight, young subjects with a hypothetical 
100% of their insulin secretory capacity. Second, the major contributors to fasting 
insulin and glucose concentrations are the pancreas and liver, not skeletal muscle. 
This was, in fact, clearly stated by Turner in the original work (Turner 1979). 
Among	others,	we	have	confirmed	this	by	comparing	HOMA-IR	with	clamp	glucose	
uptake in 467 subjects with varying degrees of glucose tolerance (Tripathy 2004). 
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The quantitative insulin sensitivity check index QUICKI
Developed and published by Arie Katz et al. from NIH in Bethesda, MD, and the 
University of Indiana, USA, QUICKI stands for the quantitative insulin sensitivity 
check index. The equation is analogous to HOMA-IR in that it is based upon fasting 
glucose and insulin values (Katz 2000): QUICKI =  1log(insulin) + log(glucose)  (Equation 13)
In the original study, the authors found QUICKI to be as representative, if not 
better, a measure of insulin sensitivity as HOMA-IR, when benchmarked against 
hyperinsulinaemic euglycaemic clamp and FSIVGTT (Katz 2000). However, both 
QUICKI and HOMA-IR solely use fasting glucose and insulin concentrations and 
they only differ from each other in the constants used.
Non-steady-state methods
Oral glucose tolerance test (OGTT)
Details of the OGTT method are given in Section 8.1.3. OGTT-derived indices used 
for the estimation of insulin sensitivity include indexes by Matsuda, Stumvoll, 
Belfiore,	Cederholm,	Gutt	and	Soonthornpun.
Matsuda (Matsuda–DeFronzo) index
This index was developed by Masafumi Matsuda and Ralph DeFronzo from the 
University of Texas (Matsuda 1999). While incorporating both fasting and mean 
glucose and insulin concentrations without the need for modelling, the Matsuda 
index (or insulin sensitivity index) has been widely applied to estimate insulin 
sensitivity from OGTT data:
 
ISI = 10000
�((fasting glucose ∙ fasting insulin) ∙ (mean glucose ∙ mean insulin))  (Equation 14)
The correlation between ISI and glucose uptake measured using euglycaemic 
hyperinsulinaemic clamp tests was 0.73 in the original study (Matsuda 1999) and 
similar associations have been observed in other research as well (Lorenzo 2010, 
Henderson 2011). 
Stumvoll index
Michael Stumvoll from the University of Tubingen, Germany, with a collaborative 
group	from	five	universities	in	Europe	and	USA,	performed	a	multiple	regression	
analysis, where OGTT insulin and glucose values were used as independent 
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parameters and clamp and anthropometric data as dependent parameters (Stumvoll 
2000). The authors later returned to their data, and presented, in a letter to Diabetes 
Care, a series of equations with a reduced set of time points, with and without 
information on BMI (Stumvoll 2001). The original index relates the clamp metabolic 
clearance rate of glucose (MCR) with information from OGTT and BMI as follows: MCR = 18.8− 0.271 ∙ BMI− 0.0052 ∙ insulin120min − 0.27 ∙ glucose90min 
 (Equation 15)
Although appealing, the equation is based on data from only 104 Caucasian subjects.
Belfiore index
Francesco	Belfiore	et	al.	from	the	University	of	Catania,	Italy,	combined	two	insulin	
sensitivity indices, one calculated using OGTT insulin and glucose values and the 
other	using	insulin	and	FFA	values	(Belfiore	1998).	The	equations	are	as	follows: ISI(gly) = 2
𝐼𝐼𝐼𝐼𝐼𝐼𝑝𝑝∙𝐺𝐺𝐺𝐺𝐺𝐺𝑝𝑝
+ 1  (Equation 16)
 
ISI(ffa) = 2
𝐼𝐼𝐼𝐼𝐼𝐼𝑝𝑝 ∙ 𝐹𝐹𝐹𝐹𝐹𝐹𝑝𝑝
+ 1  (Equation 17)
where ISI(gly) is the insulin sensitivity based on insulin-corrected glycaemia level 
and ISI(ffa) is insulin sensitivity based on the insulin-corrected FFA level. INSp is 
the population mean-corrected OGTT insulin area, GLYp is the OGTT glucose area 
and FFAp the OGTT FFA area. The areas can be calculated using a minimum of 
two OGTT time points (e.g. 0 and 2 hours). The authors emphasized the clinical 
applicability of the indices, compared to gold standard methods like euglycaemic 
hyperinsulinaemic clamp testing. They also recommended that each clinical centre 
should estimate the local population’s reference values. In comparison with other 
indices,	the	ones	by	Belfiore	have	produced	equivalent	results	as	glucose	uptake	
measured using clamp testing (Soonthornpun 2003). 
Cederholm index
Like	 the	Belfiore	 index,	 the	 one	 by	 Jan	Cederholm	 and	Lars	Wibell	 from	 the	
University of Uppsala, Sweden, can be applied to OGTTs where only fasting and 
2-hour samples are available (Cederholm 1985). There are two forms of the index: 
𝑀𝑀 =  glucose load120  + �glucose0 − glucose2h� ∙ 1.15 ∙ 180 ∙ 0.19 ∙ weight120    
 
 (Equation 18)
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𝑀𝑀 = 625 + �glucose0 − glucose2h� ∙ 0.19 ∙weight ∙ 𝐴𝐴  (Equation 19)
where M is the metabolized glucose and the glucose load is the amount of oral 
glucose. The constants are: 1.15 is to transform whole blood values to plasma values, 
180 is to transform glucose mmol to mg values, 0.19 is to convert the volume of the 
glucose compartment from the body weight and 120 is convert to values per minute. 
Equation 19 applies when standard 75 g OGTT is used. Constant A depends on 
glucose	measurement	and	on	the	units	used.	A	specific	feature,	and	also	limitation,	
of the Cederholm index is that it does not include any insulin parameters at all.
Gutt index
An insulin sensitivity index developed by Miriam Gutt et al. in 2000 is another 
example that uses only a fasting OGTT and 2-hour concentrations (Gutt 2000). The 
equation for the Gutt index, ISI0,120, is in practice a Cederholm index normalized 
for both mean glucose and log(insulin):
 
ISI0,120 = MCRlogMSI = 𝑚𝑚 MPG�logMSI   (Equation 20)
where
 
𝑚𝑚 = �75000 mg + �glucose0 − glucose2h� ∙ 0.19 ∙ weight�120   (Equation 21)
The index uses misleading terminology. The glucose uptake by peripheral tissues is 
denoted with m, the lowercase probably chosen to distinguish it from the M-value 
(see the section on euglycaemic hyperinsulinaemic clamp testing below). MCR, the 
metabolic clearance of glucose, is, analogously to clamp testing, calculated as m/MPG 
(where MPG is the average of fasting and 2-hour glucose concentrations). This is then 
normalized by log(MSI) (where MSI is the average of the fasting and 2-hour insulin 
concentrations),	which	bears,	finally,	no	analogy	to	clamp	studies:	studies	on	glucose	
uptake normalized for both mean glucose and insulin concentrations are not available. 
Soonthornpun index
Like the Gutt index, the index developed by Supamai Soonthornpun, from the 
Prince of Songkla University, Thailand, imitates the clamp approach by taking into 
account the loss of glucose to urine and by correcting glucose disposal for insulin 
levels and for the glucose distribution volume (Soonthornpun 2003). The plasma 
samples are taken every 30 min for 3 hours after a conventional 75 g oral glucose 
load. The index is calculated using:
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ISIOGTT = ��1.96 weight ∙ fgluc� + �520 ∙ 1.918 weight ∙ AUCgluc� − �𝑈𝑈gluc1.8 �� ∙ 1000(AUCins −weight)  
 (Equation 22)
where fgluc is the fasting glucose, AUCgluc is the OGTT glucose area, Ugluc is the 
urinary loss of glucose during OGTT and AUCins is the OGTT insulin area. The 
derivation of the equation in the original article is scarcely documented and it is 
based	major	simplifications	and	assumptions.	These	include	the	proportion	of	the	
glucose load estimated to be absorbed by the intestine as well as the use of 0.19 × 
weight in the calculation of glucose space. 
Intravenous glucose tolerance test (IVGTT) and frequently sampled 
IVGTT (FSIVGTT)
Details of the IVGTT method are given in Section 8.1.3. Stefan Jörgensen and 
Tage Plum from Copenhagen used an intravenous glucose infusion (“grape sugar”) 
in the early 1920s to characterize individuals with different degrees of glycosuria 
(Jörgensen 1923). Twenty years later, a method developed by Eugene Lozner from 
Harvard Medical School included most elements of modern IVGTTs, excluding the 
insulin part (Lozner 1941). In 1962 Knud Lundbaek from the University of Århus 
described how a measure for glucose tolerance, the k-value, could be calculated 
from the half-life of the declining glucose concentration (Lundbaek 1962). 
Measures of glucose disappearance: k-value or Kg 
Originally presented by Lundbaek in 1962, the k-value is based on a one-compartment 
model and represents the glucose disappearance rate after an intravenous glucose 
bolus (Lundbaek 1962). It is calculated as:
 
𝑘𝑘 = ln glucose1 − ln(0.5 ∙ glucose1)
𝑇𝑇1/2 = ln 2𝑇𝑇1/2 = 0.693𝑇𝑇1/2   (Equation 23)
where T1/2 is the time for ln(glucose) to halve and glucose1 is the initial concentration. 
The usefulness of the k-value as a proxy for insulin sensitivity is weak, as it merely 
reflects	the	combined	influences	of	peripheral	glucose	disappearance	and	hepatic	
output (Alvarsson 2005).
Minimal model assessment of insulin sensitivity
The following includes the basic modelling used for the calculation of insulin 
sensitivity indices as presented in the original publications (Bergman 1979, Cobelli 
1986). The two-compartment model used for determining insulin and glucose 
kinetics is shown in Figure 7.
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Figure 7. Two-compartment model for insulin secretion and insulin sensitivity in the minimal model. 
According to Bergman 1979.
𝑑𝑑(𝐺𝐺)
𝑑𝑑(𝑡𝑡) = (𝑝𝑝1 − 𝑋𝑋)𝐺𝐺 + 𝑝𝑝4  (Equation 24) 
𝑑𝑑(𝑋𝑋)
𝑑𝑑(𝑡𝑡) = 𝑝𝑝2𝑋𝑋 + 𝑝𝑝3𝐼𝐼(𝑡𝑡)  (Equation 25)
The	first	equation	(24)	shows	the	change	of	glucose	(G) as a function of time (t). 
On the right side of the equation, p1	is	the	total	peripheral	glucose	flux,	which	is	
a sum of the measured glucose concentration and glucose incorporated into liver 
glycogen: 𝑝𝑝1 = −(𝑘𝑘1 + 𝑘𝑘5) . The extrapolated hepatic glucose output at basal glucose 
concentration can also be expressed as, 𝑝𝑝4 = 𝑝𝑝1𝐺𝐺𝑏𝑏  where Gb is the basal plasma 
glucose concentration. Therefore: 
𝑑𝑑(𝐺𝐺)
𝑑𝑑(𝑡𝑡) = (𝑝𝑝1 − 𝑋𝑋)𝐺𝐺 + (𝑝𝑝1𝐺𝐺𝑏𝑏)  (Equation 26)
The second equation (25) shows the change of insulin (X) in the remote (non-
measurable) compartment (I’) as a function of time (t). In the equation, p2 is the 
flux	of	insulin	out	of	the	compartment	and	p3	is	the	influence	that	the	insulin	flux	
k2	to	the	compartment	has	on	the	glucose	fluxes	k1 and k5 (via k4 and k6). I(t) is the 
time course of (measurable) plasma insulin concentration.
The insulin sensitivity indices obtained from FSIVGTT are:
SI – insulin sensitivity index: Expresses the fractional glucose disappearance 
per unit of insulin. Obtained by solving the ratio −
𝑝𝑝3
𝑝𝑝2
 
 
from Equations 25 and 26.
SG – glucose effectiveness: Expresses the quantitative enhancement of glucose 
disappearance due to an increase in the plasma glucose concentration. Obtained 
by solving p1 from the same Equations 25 and 26.
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The developers of the forearm technique, Kenneth Zierler and Reubin Andres, 
who also helped to develop the euglycaemic clamp test, later questioned the utility 
of SG by demonstrating that, in the absence of hyperinsulinaemia, hyperglycaemia 
per se does not increase forearm glucose uptake (Zierler 2002).
Other non-steady-state methods
Insulin tolerance test (ITT)
The insulin tolerance test, which follows glucose concentrations after a standardized 
intravenous dose of insulin, is one of the oldest methods for assessing insulin 
sensitivity. Cyril Macbryde from Washington University in St Louis, USA, described 
it	in	1936	and	was	probably	the	first	to	describe	to	do	so.	His	aim	was	to	identify	
those diabetic patients who became glucose intolerant under a high carbohydrate 
diet (Macbryde 1936). The method was soon applied not only to studies of insulin 
sensitivity in diabetics (Klatskin 1938) but of counter regulatory hormonal responses 
to hypoglycaemia (Mirsky 1950). The version known as the short insulin tolerance 
test, shortened to ITT, was described decades later (Akinmokun 1992).
In practice: After an overnight fast, an intravenous bolus of 0.05–0.1 units per kg 
weight of short-acting insulin is administered. Arterialized venous plasma samples 
are collected before and after the bolus every minute for 15 min. 
The glucose disappearance rate (kITT or KITT) is calculated either from the log-
transformed glucose concentrations between 3 min and 15 min (Bonora 1989) or by 
dividing ln(2) (i.e. 0.693) with the time it takes log glucose concentrations to halve, 
the same procedure that Lundbaek applied to IVGTT (Lundbaek 1962). Concerns 
about safety (hypoglycaemia) and reproducibility have prompted discussions about 
and limited the usability of ITT (Chen 1998, Alberti 1999).
Himsworth test
In the test developed by Sir Harold Himsworth, an intravenous insulin bolus is 
followed immediately by an oral glucose dose and blood glucose is measured at 
frequent intervals for 90 min. The test is used to differentiate insulin-sensitive and 
insensitive diabetes patients. 
In practice: An intravenous bolus of short-acting insulin (5 units per m2 body 
surface area) is followed by ingestion of glucose (30 g per m2 body surface area) 
dissolved in ½ pint of water. Blood samples are taken at the basal state and then 
every 10 min for 60 min, then at 75 and 90 min. 
Himsworth used dual sampling from peripheral veins and ear lobe capillaries to 
get an estimate of the capillary (arterial)–venous difference. Although interpretation 
of test results is more observatory than quantitative, Himsworth was able to 
differentiate insulin-sensitive from insensitive subjects by comparing their test 
glucose	 profiles.	 The	 time	 course	 of	 the	 capillary–venous	 differences	 further	
supported the observations (Himsworth 2011, Kim 2011). 
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If the insulin tolerance test is straightforward, representing “an American 
approach” to metabolic questions, then the Himsworth test was typically European: 
it was intricate, included several questions and as many answers. Besides Himsworth 
himself, the test has been mentioned in only a few publications, the last one probably 
being by Tan, Gerich et al. in 1980 (Tan 1980).
Meal test
Although meal tests have long been used to study glucose tolerance (Mellinkoff 1956), 
most of the study protocols have been ad hoc. No meal test protocol was available 
to estimate insulin action until in 2000 Claudio Cobelli et al. from the University 
of Padua published a meal glucose tolerance test (MGTT) with a minimal model 
approach for glucose disappearance (Caumo 2000). The approach is principally 
identical to the minimal model described above, with oral glucose or mixed meal 
input appended to the glucose time course equation in the following way:
 
𝑑𝑑(𝐺𝐺)
𝑑𝑑(𝑡𝑡) = (𝑝𝑝1 − 𝑋𝑋)𝐺𝐺 + 𝑝𝑝1𝐺𝐺𝑏𝑏 + 𝑟𝑟𝛼𝛼(𝑡𝑡)𝑉𝑉   (Equation 27) 
𝑑𝑑(𝑋𝑋)
𝑑𝑑(𝑡𝑡) = 𝑝𝑝2𝑋𝑋 + 𝑝𝑝3𝐼𝐼(𝑡𝑡)  (Equation 25)
where rα is the per unit body weight rate of entry of exogenous glucose into the 
system as a function of time and V is the distribution volume. Insulin sensitivity 
is expressed as p3/p2, as usual (Caumo 2000). The approach was later improved, 
using C-peptide instead of insulin measurements, to account for insulin secretion 
and hepatic insulin extraction as well (Cobelli 2007).
Steady-state methods
Euglycaemic hyperinsulinaemic clamp
The version of the euglycaemic hyperinsulinaemic clamp test published by Ralph 
DeFronzo, Jordan Tobin and Reuben Andres in 1979 has remained practically 
unchanged over 30 years. It is the gold standard method for estimating insulin-
stimulated glucose uptake (DeFronzo 1979).
In the test, hyperinsulinaemia is induced and a chosen plasma glucose level is 
maintained using intravenous insulin and glucose infusions. The amount of glucose 
infused	to	maintain	glycaemia	reflects	the	whole	body	glucose	uptake	and,	hence,	
characterizes the insulin sensitivity of the subject. 
In practice: A priming stepwise-decreasing infusion of short-acting insulin (100 
IU/ml) is given intravenously and followed by a steady infusion for the rest of the 
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study. Plasma glucose is analysed at the bedside at 5 min intervals. Euglycaemia 
is maintained with a variable intravenous infusion of 20% glucose. In our studies, 
plasma glucose has been kept at 5.5 mmol·l–1 and the insulin dose calculated as 45 
mU	per	min	∙	m2 of body surface area. Mean glucose and insulin concentrations 
from the last 60 min of the 120 min protocol have been used to calculate steady-
state parameters (Tripathy 2004). Glucose uptake (glucose that is “metabolized”, 
hence letter M) is calculated from the glucose infusion rate during the steady-state 
period	and	expressed	as	an	M-value	(mg	per	min	∙	kg	of	fat-free	mass),	and	often	
also as a steady-state plasma insulin concentration (M/I). 
An advantage of the clamp technique is that several components can be varied: 
insulin dose, clamp glucose level, study duration as well as accessory protocols for 
the clamp. In the original study by Sherwin, two insulin doses were used: 1 mU 
per kg weight (corresponding to 40 mU per m2) and 2 mU per kg (Sherwin 1974). 
Much higher doses of insulin, up to 4,000 mU per m2, resulting in plasma insulin 
concentrations	of	20,000	μU/ml,	have	been	used	especially	in	very	insulin-resistant	
individuals	(Bonadonna	1990).	Sherwin	et	al.	defined	euglycaemia	as	the	basal	blood	
glucose concentration of the study subject, varying over 4.7–5.6 mmol·l–1 (85–100 
mg·dl–1) (Sherwin 1974). Today, steady-state glucose concentrations of 4.0–5.5 
mmol·l–1 are called either euglycaemic or isoglycaemic: in euglycaemic individuals 
the clamp state may be called isoglycaemic, and in hyperglycaemic individuals 
euglycaemic (Riccardo Bonadonna, personal communication 18 December 2012). 
Hyperglycaemic clamp test
Details of the hyperglycaemic clamp technique can be found in Section 8.1.3. In 
hyperglycaemic clamp testing the M-value is the amount of glucose infused per 
unit weight or per fat-free mass, corrected for the amount of glucose lost in urine 
(DeFronzo 1979). Even the authors of the original paper admitted that the estimate 
of glucose uptake obtained via the hyperglycaemic clamp technique is more or less 
a measure of intravenous glucose tolerance where the glucose concentration, not 
the	amount	infused,	is	fixed.
Continuous infusion of glucose with model assessment (CIGMA)
Robert Turner presented CIGMA (Hosker 1985) back to back with HOMA (Matthews 
1985) as a short and easily manageable test of both insulin action and secretion. It 
consists of a 60-min constant intravenous low-dose infusion of glucose (5 mg per 
kg ideal body weight) with only three venous blood samples at 50, 55 and 60 min. 
Insulin resistance R	and	beta	cell	function	β	are	simply	estimated	by	reading	the	
values from a predetermined grid with plasma glucose (a mean of three measured 
values) on the x-axis and insulin on the y-axis.	Turner	designed	the	grid	by	fitting	
empirical data into a model with separate one-compartment models for both glucose 
and insulin concentrations.
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Insulin suppression test
In the test developed by Shiao-Wei Shen, Gerald Reaven and John Farquhar from 
Stanford University, endogenous insulin secretion is suppressed with a propranolol-
adrenalin infusion. Exogenous insulin is infused at a constant rate and glucose 
uptake	is	quantified	from	the	amount	of	infused	glucose	needed	to	maintain	a	steady	
plasma glucose concentration. The higher the glucose concentration during the 
steady state, the more insulin resistant the subject (Shen 1970). The interrelationship 
between glucose uptake and glucose infusion during the steady state is expressed as:
 
𝑉𝑉 = 𝑘𝑘𝑢𝑢𝐺𝐺  (Equation 28)
where V is the glucose uptake in mg per kg body weight, G is the (steady-state) 
plasma glucose concentration and ku is a diffusion constant. The impedance, that 
is the resistance to insulin action, is
 1
𝑘𝑘𝑢𝑢
 
 (Equation 29)
In	a	modification	of	the	test	by	Yukio	Harano,	the	propranolol-adrenalin	infusion	
was substituted by somatostatin (Harano 1977). KGMM Alberti used somatostatin 
to suppress endogenous insulin secretion in 1973 (Alberti 1973). This was later 
modified	for	the	somatostatin	version	of	the	insulin	suppression	test	(Heine	1985).
Limb balance techniques
The method developed by Reubin Andres, Gordon Cader and Kenneth Zierler from 
Johns Hopkins University (Andres 1956) is still in use today (Vicini 1998, Zierler 
2002). It requires cannulation of both the brachial artery and a deep forearm vein 
and	exclusion	of	blood	flow	distal	 to	the	wrist.	An	indicator	dye	 is	used	for	the	
simultaneous	measurement	of	blood	flow	(F) through the forearm. The method 
is based upon the Fick principle: the rate of substrate use is proportional to the 
product	of	flow	and	difference	between	output	and	input	(Andres	1956).	The	rate	
of glucose metabolized per unit of forearm (limb) mass can thus be expressed as:
  
?̇?𝑄𝑀𝑀 = 𝑎𝑎𝑏𝑏 ∙ 𝐹𝐹𝑇𝑇 ∙ (𝐴𝐴 − 𝑉𝑉𝑀𝑀)𝑀𝑀𝑇𝑇   (Equation 30)
where FT	 is	 the	total	 forearm	flow,	A is the glucose concentration in the artery, 
VM is the deep vein glucose concentration, MT is the total forearm mass, a is the 
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fraction	of	the	total	flow	perfusing	muscle	and	b is the fraction of muscle mass in 
the forearm (Andres 1956).
History: The effect of insulin on arterio-venous (A-V) difference in glucose 
concentration was studied soon after the discovery of insulin (Cori 1928). 
Himsworth used the capillary–venous difference in his glucose tolerance test 
(Himsworth 2011). In 1950 Michael Somogyi from St Louis Jewish Hospital 
described	the	influence	of	subcutaneous	epinephrine	on	the	glucose	A-V	difference	
(Somogyi 1950) and the fundamentals of the modern limb balance technique were 
described 6 years later by Andres (Andres 1956), who, more than 6 years later, 
also characterized insulin action on forearm glucose uptake (Andres 1962). In 
1990, Alain Baron with post-doctoral student Markku Laakso from Indianapolis 
University used the forearm technique to estimate leg glucose uptake in obese 
individuals (Laakso 1990).
Combined methods
Although a combination of hyperglycaemic and euglycaemic clamp techniques 
would represent the gold standard for assessing insulin secretion and action, they 
are so time-consuming and invasive that they must be performed on separate days. 
Therefore, there is a need for cost-effective and simple measurements of insulin 
secretion and action during a single study session.
Botnia clamp technique
The Botnia clamp technique is a combination of an IVGTT (samples at 0, 2, 4, 6, 
8,	10,	20,	30	and	40	min)	followed	by	a	conventional	2-hour,	45	mU	per	min	∙	m2 
hyperinsulinaemic euglycaemic clamp, which begins after 60 min (Tripathy 2003). It 
yields	the	conventional	first-phase	insulin	response	to	intravenous	glucose	(dose	0.3	
g·kg–1),	calculated	as	the	incremental	rise	in	insulin	concentration	during	the	first	10	
min, as well as a second-phase insulin response, calculated as the incremental rise 
in insulin concentration between 10 and 60 min. Glucose uptake is measured from 
the glucose infusion rate during the last 60 min of the clamp. As insulin secretion 
and insulin sensitivity are measured during a single test, a disposition index can 
be	estimated	as	the	product	of	the	first-phase	insulin	secretion	and	glucose	uptake	
(Tripathy 2003).
FSIVGTT and minimal model 
FSIVGTT and the minimal model have been described in Section 8.1.3 and earlier 
in the current section.
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Glucagon-stimulated C-peptide test and insulin-tolerance test (GITT)
Compared to the Botnia clamp test and FSIVGTT, a shorter method was recently 
proposed by Mozhgan Dorkhan from Malmö University Hospital (Dorkhan 2008). 
A low-dose glucagon bolus is administered (0.5 mg) followed 30 min later by a low-
dose insulin bolus (0.05 IU per kg of short-acting human insulin). C-peptide and 
glucose levels are sampled at 0, 6, 30, 31, 33, 35, 37, 39, 41, 43, 45, 50 and 60 min. 
The incremental C-peptide level at 6 min is used as a beta cell response to glucagon 
and the slope of the regression line of the glucose concentration after insulin bolus 
at 30 min is used for the calculation of insulin sensitivity, expressed as a K-value 
or KITT. The authors show that, unlike IVGTT and hyperglycaemic clamp testing, 
GITT can also be used for subjects with type 2 diabetes, whose impaired beta cell 
function	influences	both	the	assessment	of	insulin	secretion	and	insulin	sensitivity.
Meal test 
The meal test has been described under steady-state methods.
8.1.5 REPRODUCIBILITy OF ASSESSmENT mETHODS 
Goodarzi et al. demonstrated recently, that fasting insulin concentration in Mexican 
Americans	was	influenced	by	several	factors	including	BMI,	glucose	uptake,	insulin	
clearance, fasting glucose and waist circumference (Goodarzi 2011). The authors 
warranted that interpretation of insulin action and secretion measures based on 
fasting	insulin	should,	therefore,	be	done	with	caution.	In	general,	the	coefficient	
of variation (CV) for fasting insulin and related indices has varied between 7.8 and 
19.0 %, respectively (Bonora 2000, Tripathy 2003).  The interindividual variation of 
clamp FSIVGTT have varied from study to study, with CV’s for the former ranging 
between 14.4% (Ferrari 1991) and 20.2% (Steil 1994), and for the latter between 
9.0% (Tripathy 2003) and 38% (Morris 1997), respectively. The intra-individual 
CV	for	the	first	phase	insulin	(FPI)	secretion,	calculated	as	the	incremental	area	
under	insulin	curve	during	the	first	10	min	of	an	IVGTT,	has	varied	between	6.0%	
(McNair 1995) and 27% (Tripathy 2003), respectively.
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8.2 mETHODOLOGy FOR THE STUDy OF VARIABILITy AmONG 
INDIVIDUALS
8.2.1 HISTORy OF QUANTITATIVE GENETICS
Augustinian priest Gregor Johann Mendel (1822–1884) from Brno, in what now 
is	the	Czech	Republic,	was	the	first	to	study	the	ratio	of	different	trait	variants	in	
consecutive generations. He wrote: “Pea hybrids form germinal and pollen cells 
that in their composition correspond in equal numbers to all the constant forms 
resulting from the combination of traits united through fertilization” (Stern 1966). 
This incorporates the principles now known as Mendel’s laws of segregation and 
independent assortment. Mendel did not receive recognition from his colleagues 
and almost 35 years passed until 1900, when three scientists, DeVries, Correns 
and Tschermak, independently replicated Mendel’s results and credited him for 
the original work (Roberts 1929).
The mathematical modelling of inheritance is based upon the work of Sir 
Francis Galton (1822–1911), a half-cousin of Darwin. He published 340 works 
and introduced the concepts of regression and correlation for studying continuous 
variation in humans (Galton 1889). Galton’s work was developed by his co-worker 
Karl Pearson (1857–1936). Pearson showed that what Galton meant by regression, 
designated by the letter r, was actually (Pearson’s) correlation (Magnello 2004). In 
1901	Galton,	Pearson	and	Walter	Weldon	(1860–1906)	founded	the	scientific	journal	
Biometrika, which published articles about the biometrical theory of inheritance. 
They postulated that both near and distant relatives contributed to heredity and 
that	trait	variation	in	a	population	was	continuous.	This	was	fiercely	opposed	by	the	
Mendelians, who claimed that distinct hereditary units must yield discontinuous 
variation (Rushton 2000). The Mendelians were led by an embryologist from St 
Johns College, Cambridge, William Bateson (1861–1925), who in 1905 coined 
the	term	genetics,	and	in	1908	became	the	world’s	first	professor	of	Genetics,	at	
Cambridge	University.	Bateson	worked	with	Hugo	de	Vries,	the	first	scientist	to	
use the term mutation (de Vries 1902).
The debate between the biometricians and the Mendelians came to end only 
when a British statistician, Ronald A. Fisher (1890–1962), credited as probably 
the	most	 influential	statistician	of	 the	20th	century,	solved	the	discrepancies	 in	
a groundbreaking article “The correlation between relatives on the supposition 
of Mendelian inheritance” (Fisher 1918). During his almost 50-year career Fisher 
introduced several statistical methods and concepts, including the distribution 
of	correlation	coefficient,	maximum	likelihood,	analysis	of	variance	and	(Fisher)	
information (Fienberg 1980). His book The Genetical Theory of Natural Selection 
(Edwards 2000), which Fisher dictated and his wife wrote down, is regarded as 
one	of	 the	most	 important	scientific	publications	since	Darwin’s	On the Origin 
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of Species (Fisher 1999). It was a comprehensive synthesis of Darwin’s theory 
of evolution and natural selection and Mendel’s theory of heredity, tied together 
using biometrical statistics. Fisher, Sewall Wright (1889–1988) and John B.S. 
(Jack) Haldane (1892–1964) are regarded as the founders of theoretical population 
genetics.	Wright	introduced	concepts	like	the	inbreeding	coefficient,	genetic	drift	
and path analysis (Wright 1921, 1931, 1934).
Genetic epidemiology would not exist in its present form without the 
contributions of a German physician, geneticist and twin-study pioneer, Wilhelm 
Weinberg (1862–1937), and a British mathematician, Godfrey H. Hardy (1877–
1947). Weinberg, owing to his clinical work in helping those who could not afford 
proper health care, had already become acknowledged for his studies on cancer 
and had been developing a differential method for determining the frequencies in 
twinning (Mayo 2008). In January 1908 he presented a paper where he derived the 
general equilibrium principle for a single locus with two alleles (Provine 1971). In 
February 1908, Bateson’s co-worker in Cambridge, zoologist Reginald C. Punnett 
(1875–1967), was asked after a lecture in London why recessive phenotypes were 
not removed from the population. Punnett was not able to answer satisfactorily, 
and turned to his friend in Cambridge, G.H. Hardy, who answered (with “a little 
mathematics of the multiplication-table type”) that “if the parental genotypic 
proportions were p AA : 2q Aa : r aa, then they would be (p + q)2 : 2(p + q)(q + 
r) : (q + r)2 among the offspring” (Edwards 2008). As Nature was at that time a 
hostile publishing environment for Mendelians, Hardy published his result in the 
July 1908 issue of the journal Science (Hardy 1908). The multiplication table for 
the calculation of genotypic proportion, the “checkerboard”, has since the 1950s 
been named Punnett’s square (Davis 1993).
The development of quantitative genetics speeded up when Fisher brought 
geneticist Kenneth Mather (1911–1990) as a lecturer to University College, London, 
in 1934. In collaboration with his student John L. Jinks (1929–1987), in 1971 Mather 
wrote the book Biometrical Genetics	(Mather	1982),	the	first	version	of	which	Mather	
had	written	on	his	own	in	1949	(Mather	1949).	While	the	model-fitting	developed	
by Mather and Jinks was applicable to plants, David W. Fulker (1937–1998), a 
student of Jinks, applied biometrical models to human behavioural genetics (Jinks 
1970). Norton E. Morton from the University of Hawaii implemented path analysis 
in biometrical modelling (Morton 1974, 1974a, 1974b, Rao 1974, 1974a, MacLean 
1975). Norton’s work was followed by three publications from John Rice, Robert 
Cloninger and Theodore Reich from Washington University (Rice 1978, Cloninger 
1979a, 1979b), where they described a general linear model of familial resemblance, 
allowing for cultural transmission from parent to offspring, polygenic inheritance, 
phenotypic assortative mating, common environment, maternal and paternal effects, 
threshold effects and genic-cultural correlation. When, Nicholas Martin and Lindon 
Eaves from the University of Birmingham published their work in 1977, in which 
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the analysis of covariance structures was adapted to the simultaneous maximum 
likelihood	estimation	of	genetical	and	environmental	 factor	 loading	and	specific	
variances (Martin 1977), the methodology in genetic epidemiology for studying 
resemblance between relatives had practically been laid out. 
Karl Jöreskog, then in Princeton, NJ, working on covariance structures, produced 
the	first	computer	algorithms	 for	parameter	estimation	and	hypothesis-testing	
(Jöreskog 1973). The collaboration between Jöreskog (1972) and Dag Sörbom at 
the University of Uppsala, Sweden, led to the development of the computer program 
LISREL (linear structural relations; http://www.ssicentral.com/lisrel/references.
html), which went through several versions and became the most used tool for 
structural equation modelling (SEM) during the 1970s and 1980s. In 1990, based 
partly upon his experience in using and teaching LISREL, Michael Neale from 
Virginia Commonwealth University, together with Steve Boker, began to develop 
the Mx software, which among other features provided a graphical user interface 
for drawing path diagrams prior to the statistical processing of the models (Neale 
1992, 2004). Mx became the most used SEM program during the 1990s, and since 
then it has become the core of OpenMx, open-source software for estimating a wide 
variety of advanced multivariate statistical models (http://openmx.psyc.virginia.
edu) (Boker 2011).
8.2.2 TWIN STUDIES
The	credit	of	the	first	scientific	publication	to	use	twin	data	is	usually	given	to	Sir	
Francis Galton (Galton 1875) although he recommends the paper Die Lehre von 
den Zwillingen	by	Dr	Ludwig	Kleinwächter	(Kleinwächter	1871).	Possibly	the	first	
twin study where the twins were tested was conducted by Edward Thorndike in 
1905 (Thorndike 1905). A systematic presentation of what is now known as the 
classical twin method, was in 1924 described independently by Hermann Werner 
Siemens (Siemens 1924) and Curtis Merriman (Merriman 1924). The same year, 
the	first	Norwegian	female	professor,	Kristine	Bonnevie,	studied	fingerprint	patterns	
using	twin	pair	data,	and	proposed	them	to	be	a	result	of	polygenic	 influences	
(Bonnevie 1924). 
The	first	 large	twin	study	was	performed	and	published	as	a	monograph	by	
Horatio Newman, Frank Freeman and Karl Holzinger from the University of Chicago 
(Newman 1937). The twins were followed for 10 years, their physical measures 
recorded, parents interviewed and an array of psychological characteristics estimated. 
The statistical methods included analysis of concordance and discordance, and 
the estimation of heritability with analysis of variance (ANOVA), as developed by 
Holzinger. The ANOVA method was the prevailing one until the introduction of 
structural modelling during the 1970s. In addition to the main study, which included 
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50 identical (MZ) and 50 fraternal (DZ) twin pairs, Newman also published, in a 
series of articles in the Journal of Heredity	between	1929	and	1940,	the	first	study	
of 19 twin pairs reared apart (Newman 1937).
In Finland, psychologist Arvo Lehtovaara from the University of Jyväskylä 
published	the	first	twin	studies	in	1938	in	the	form	of	a	doctoral	thesis.	He	studied	
psychological and behavioural traits of 144 twin pairs between the ages of 3 months 
and 17 years (Lehtovaara 1938). The Finnish Foundation for Alcohol Studies funded 
a study between 1958 and 1960, consisting of all male twin pairs (n = 1050) born 
between	1920	and	1929.	A	series	of	publications	followed,	including	also	the	first	
Finnish twin studies on blood glucose and serum cholesterol (Sammalisto 1961, 
Pikkarainen 1964a, 1964b, Kumento 1965, Partanen 1966, Pikkarainen 1966, 
Kulonen 1967, Frey 1968). The latter studies were performed independently before 
the launch of the Finnish Twin Cohort Study in 1974 (Sarna 1976, Koskenvuo 1976, 
Sarna 1978, Kaprio 1978), of which the current thesis is part.
8.2.3 HERITABILITy
The detailed theory of the genetic epidemiology used in this study is available in 
several textbooks (Falconer 1996, Khoury 1993, Neale 2004) and only a couple of 
conceptual issues will be covered here.
The study of familial resemblance in genetic epidemiology aims at answering 
questions about the degree and causes of similarities and differences between parents 
and their children and between children within families (Khoury 1993). Genetic 
epidemiology asks: How important are genetic effects on human differences? What 
kind of actions and interactions occur between gene products in the pathways 
between genotype and phenotype? Are the genetic effects on a trait consistent across 
sexes? It does not, on the other hand, try to give answers to questions about which 
genes cause what or where in the genome they might be found (Neale 2004). 
The use of the terminology in the current study follows that presented by John 
Fuller and William Thompson in their textbook of behavioural genetics (Fuller 
1979): phenotypes are observable characteristics, genotypes are the chromosomal 
complements	of	gene	alleles.	Genes	are	the	unit	factors	of	inheritance	influencing	
observable traits. Alleles are maternal or paternal forms of genes in the same locus on 
a chromosome. The Hardy–Weinberg equilibrium (HWE) holds, that is, allele and 
genotypic	frequencies	remain	unchanged	in	an	(infinitely)	large	population	where	
migration and mutation are not acting and other selective forces do not exist (Stern 
1943). In theory, random mating is also assumed, though recent studies show that 
certain types of non-random mating allow the HWE to be maintained (Li 1988), 
or that random mating is merely an extreme case of non-random mating (Stark 
2006). The preconditions used for the structural equation modelling are: the genes 
64
LEHTOVIRTA – Heritability of Type 2 Diabetes and Related Traits
and environmental effects are independent, environmental effects are independent 
across individuals and the polygenic effect is due to many independent additive 
genetic effects each of small size.
Definition of the statistics of similarity
Table 5 lists the explanations and equations for the most common twin statistics, 
which also are the basic interactions used in the path models. The core statistic 
of twin data is covariance, which is a measure of how values for each twin pair 
differ from the respective population (sample) means. Correlation is the covariance 
corrected with the standard deviation. Variance is a special covariance as it is the 
covariance of a variable with itself.
Table 5. Basic statistics used in the quantitation of similarity between relatives.
Statistic, symbol Definition Equation 
numberEquation
Mean, x̅ Arithmetic mean of a distribution (𝑥𝑥1 + 𝑥𝑥2 + 𝑥𝑥3 +⋯+ 𝑥𝑥𝑛𝑛)
𝑛𝑛
 Equation 31
Variance, s2 or VMZ or VDZ Variability of a trait, a measure of the spread of individual values [(𝑥𝑥1 − ?̅?𝑥)2 + (𝑥𝑥2 − ?̅?𝑥)2 + (𝑥𝑥3 − ?̅?𝑥)2 +⋯+(𝑥𝑥𝑛𝑛 − ?̅?𝑥)2]
𝑛𝑛 − 1  Equation 32
Covariance, sx,y or 
CovMZ or CovDZ A measure of how much sets of variables change together [(𝑥𝑥1 − ?̅?𝑥) ∙ (𝑦𝑦1 − 𝑦𝑦�) + (𝑥𝑥2 − ?̅?𝑥) ∙ (𝑦𝑦2 − 𝑦𝑦�) +⋯+ (𝑥𝑥𝑛𝑛 − ?̅?𝑥) ∙ (𝑦𝑦𝑛𝑛 − 𝑦𝑦�)]
𝑛𝑛 − 1  Equation 33
Correlation, r Covariance, normalized by the deviation of observations from the mean 
𝑠𝑠𝑥𝑥,𝑦𝑦
��𝑠𝑠𝑥𝑥
2 ∙ 𝑠𝑠𝑦𝑦
2�
 
Equation 34
Standard 
deviation, SD Square root of variance
������ � �̅�
� � ��� � �̅�� � ��� � �̅�� � ����� � �̅���
� � � �  Equation 35
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Genotypes and population frequencies
In a randomly mating population under HWE, the genotypic effect is thought to be 
a measurable property that is dependent on the gene dose, i.e. the presence of 0, 1 
or 2 dominant alleles in a gene locus plus additive or dominant effects that deviate 
the heterozygote genotypic effect from the midpoint between the two homozygotes. 
A schematic representation is shown in Figure 8.
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Figure 8. Graphical representation of the relations between gene dose of homozygotes and 
heterozygotes and the genotypic effect in a one-locus model with two alleles (Neale 2004). With 
permission from Springer Netherlands.
Consider a one-locus, two-allele model with genotypes AA, Aa and aa, respectively. 
The homozygotes (AA, aa) cause, on the population level, a deviation from the 
trait mean m. The heterozygote (Aa) causes a deviation h (h > m or h < m). In 
case where h	≠	m, it is assumed that the alleles A and a have unequal effects on 
the trait. This is called dominance. The dots represent the observed values of the 
genotypes plotted against the gene dose. The allele A is considered to increase the 
trait	value.	A	regression	line	has	been	fitted	using	least	squares.	In	HWE,	with	allele	
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frequencies u for A, and v for a, for the genotypes AA, Aa and aa, with genotypic 
effects d, h, –d and gene A doses of 2, 1, 0, the genotypic frequencies are u2, 2vu 
and v2, respectively. 
Decomposition of variances
In short, under the preconditions listed above, SEM is based on the following: MZ 
twins share all their genes and gene combinations. On average, DZ twins as well as 
full sibs share half, half sibs a quarter and parents and offspring half of their genes 
and gene combinations, respectively. Unrelated siblings (children with different 
biological	parents	but	raised	by	common	parents)	do	not	share	genetic	influences.
1. The shared environment is assumed to be similar between all siblings reared 
together.
2. The variance of a trait can be partitioned to latent genetic and environmental 
effects.
3. The genetic variance can further be partitioned to additive variance, variance 
due to dominance and variance due to epistasis, i.e. the interaction of loci 
over different alleles:  
𝑉𝑉𝐺𝐺 = 𝑉𝑉𝐴𝐴 + 𝑉𝑉𝐷𝐷 + 𝑉𝑉𝐼𝐼  (Equation 36)
4. The	 variance	 due	 to	 environmental	 influences	 can	 be	 partitioned	 into	
variance shared between family members, variance due to repetitive 
measures	and	unique	environmental	influences	including	error: 
𝑉𝑉𝐶𝐶 + 𝑉𝑉𝑅𝑅 + 𝑉𝑉𝐸𝐸   (Equation 37)
5. In case gene-environment covariation and gene-environment interaction 
are also included, the total phenotypic variance of a trait, VP, can, thus, be 
decomposed as to: 
𝑉𝑉𝑃𝑃 = 𝑉𝑉𝐴𝐴 + 𝑉𝑉𝐷𝐷 + 𝑉𝑉𝐼𝐼 + 𝑉𝑉𝐶𝐶 + 𝑉𝑉𝑅𝑅 + 𝑉𝑉𝐸𝐸 + 2𝑉𝑉𝐺𝐺,𝐸𝐸 + 𝑉𝑉𝐺𝐺×𝐸𝐸2   (Equation 38)
6. The covariance between two family members is:Cov(𝑌𝑌1,𝑌𝑌2) = 2 ∙ 𝛷𝛷𝑖𝑖𝑖𝑖 ∙ 𝑉𝑉𝐺𝐺   (Equation 39)
where	the	term	Φij is	the	theoretical	kinship	coefficient.
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In most twin studies VI, VR and covariance and interaction between genes and 
environment cannot be estimated (Visscher 2008).
Table 6. Equations for calculation of covariance between relatives.
Covariance between relatives both using allele frequencies and genotypic effects (I) and 
variance components (II)
CovMZ 
I 2𝑢𝑢𝑢𝑢[𝑑𝑑 + (𝑢𝑢 − 𝑢𝑢)ℎ]2 + 4𝑢𝑢2𝑢𝑢2ℎ2 Equation 40
II 𝑉𝑉𝐴𝐴 + 𝑉𝑉𝐷𝐷 Equation 41
CovDZ
I 𝑢𝑢𝑢𝑢[𝑑𝑑 + (𝑢𝑢 − 𝑢𝑢)ℎ]2 + 𝑢𝑢2𝑢𝑢2ℎ2 Equation 42
II
12𝑉𝑉𝐴𝐴 + 14𝑉𝑉𝐷𝐷 Equation 43
Covunrelated 
siblings
I 0 Equation 44
II 0 Equation 45
Covhalf sibs
I
12𝑢𝑢𝑢𝑢[𝑑𝑑 + (𝑢𝑢 − 𝑢𝑢)ℎ]2 Equation 46
II
14𝑉𝑉𝐴𝐴 Equation 47
Covparent-offspring
I 𝑢𝑢𝑢𝑢[𝑑𝑑 + (𝑢𝑢 − 𝑢𝑢)ℎ]2 Equation 48
II
12𝑉𝑉𝐴𝐴 Equation 49
Bivariate model
With two traits, it is possible to observe variances of the individual traits, correlations 
and covariances of the same traits between twins as well as the cross-twin cross-
trait (ctct) correlations and covariances. Table 7 is an elegant summary by Peter 
Visscher of the population correlations for MZ and DZ twins in a bivariate model. 
The correlations are displayed separately for three variance component models: 
AE, CE and ACE, which represent the partitioning of the total phenotypic variance 
VP to either VA + VE (AE), VC + VE (CE, no genes involved) or VA + VC + VE (ACE).
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Table 7. Population correlations in terms of bivariate model parameters for MZ and DZ twins.
Correlation
Model for both x and y Equation 
numbersAE CE ACE 
𝑟𝑟𝑥𝑥(MZ)= ℎ𝑥𝑥2 𝑐𝑐𝑥𝑥2 ℎ𝑥𝑥2 + 𝑐𝑐𝑥𝑥2 Equations 50–52  
𝑟𝑟𝑥𝑥(DZ)= 
 
12 ℎ𝑥𝑥2 𝑐𝑐𝑥𝑥2 12 ℎ𝑥𝑥2 + 𝑐𝑐𝑥𝑥2 Equations 53–55  
𝑟𝑟𝑦𝑦(MZ)= 
 
ℎ𝑦𝑦
2  
 
𝑐𝑐𝑦𝑦
2 ℎ𝑦𝑦2 + 𝑐𝑐𝑦𝑦2 Equations 56–58  
𝑟𝑟𝑦𝑦(DZ)= 
 
12 ℎ𝑦𝑦2  𝑐𝑐𝑦𝑦2 12 ℎ𝑦𝑦2 + 𝑐𝑐𝑦𝑦2 Equations 59–61  
𝑟𝑟𝑥𝑥𝑥𝑥(MZ)= 
 
 
𝑟𝑟𝑔𝑔ℎ𝑥𝑥ℎ𝑦𝑦 𝑟𝑟𝑐𝑐𝑐𝑐𝑥𝑥𝑐𝑐𝑦𝑦 𝑟𝑟𝑔𝑔ℎ𝑥𝑥ℎ𝑦𝑦 + 𝑟𝑟𝑐𝑐𝑐𝑐𝑥𝑥𝑐𝑐𝑦𝑦 Equations 62–64 
𝑟𝑟𝑥𝑥𝑥𝑥(DZ)= 
 
 
 
12 𝑟𝑟𝑔𝑔ℎ𝑥𝑥ℎ𝑦𝑦 𝑟𝑟𝑐𝑐𝑐𝑐𝑥𝑥𝑐𝑐𝑦𝑦 12 𝑟𝑟𝑔𝑔ℎ𝑥𝑥ℎ𝑦𝑦 + 𝑟𝑟𝑐𝑐𝑐𝑐𝑥𝑥𝑐𝑐𝑦𝑦 Equations 65–67 
𝑟𝑟𝑝𝑝= 
 
 
 
𝑟𝑟𝑔𝑔ℎ𝑥𝑥ℎ𝑦𝑦 + 𝑟𝑟𝑒𝑒𝑒𝑒𝑥𝑥𝑒𝑒𝑦𝑦 𝑟𝑟𝑐𝑐𝑐𝑐𝑥𝑥𝑐𝑐𝑦𝑦 + 𝑟𝑟𝑒𝑒𝑒𝑒𝑥𝑥𝑒𝑒𝑦𝑦 𝑟𝑟𝑔𝑔ℎ𝑥𝑥ℎ𝑦𝑦 + 𝑟𝑟𝑐𝑐𝑐𝑐𝑥𝑥𝑐𝑐𝑦𝑦 + 𝑟𝑟𝑒𝑒𝑒𝑒𝑥𝑥𝑒𝑒𝑦𝑦 = 𝑟𝑟𝑝𝑝 Equations 68–70
Published with the permission from Peter Visscher (Visscher 2006).
The variance ratios in the population are denoted hi
2, ci
2 and ei
2, for traits I = x, 
y. The covariance ratios are rghxhy, rccxcy, and reexey. Hence, rg, rc, and re are the 
correlations of the additive genetic effects, common environmental effects and 
individual environmental effects, respectively. The total variance ratio is equal to 
one, i.e. 
ℎ𝑖𝑖
2 + 𝑐𝑐𝑖𝑖2 + 𝑒𝑒𝑖𝑖2 = 1  (Equation 71)
The sum of covariance ratios, i.e. the products of the covariances and correlations of 
the respective additive genetic, common environmental and unique environmental 
effects, sum up to rp, the correlation between x and y in the population, measured 
for the same individual:
𝑟𝑟𝑔𝑔ℎ𝑥𝑥ℎ𝑦𝑦 + 𝑟𝑟𝑐𝑐𝑐𝑐𝑥𝑥𝑐𝑐𝑦𝑦 + 𝑟𝑟𝑒𝑒𝑒𝑒𝑥𝑥𝑒𝑒𝑦𝑦 = 𝑟𝑟𝑝𝑝  (Equation 70)
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Heritability
Heritability is the proportion of the total variance of a trait that is explained by 
genetic	influences.	In	the	absence	of	non-additivity,	heritability	in	the	narrow	sense	
is written as:
ℎ2 = 𝑉𝑉𝐴𝐴
𝑉𝑉𝑃𝑃
  (Equation 72)
The proportion of the total genotypic variance of the total phenotypic variance is 
the heritability in the broad sense:
𝐻𝐻2 = 𝑉𝑉𝐺𝐺
𝑉𝑉𝑃𝑃
  (Equation 73)
Intraclass correlations and concordances
A	simplified	approach	is	to	compare	MZ	and	DZ	intraclass	(intrapair)	correlations,	
where the trait value of twin 1 is correlated to the value of twin 2 within a twin 
pair.	This	method	is	less	accurate	than	the	model-fitting	procedure,	because	the	
correlation	coefficient	is	a	function	of	both	covariances	and	variances	(Neale	2004),	
but lends itself to easier interpretation. In the presence of purely additive genetic 
variance	(besides	non-genetic	influences	from	the	unique	environment):intraclass 𝑟𝑟(MZ) = 2 ∙ intraclass 𝑟𝑟(DZ)  (Equation 74) 
Environmental factors shared by the twins tend to decrease the ratio of intraclass 𝑟𝑟(MZ)intraclass 𝑟𝑟(DZ)  , whereas non-additive genetic factors increase it (Neale 2004).
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Table 8. Explanation of other statistics used for quantitation of similarity between twins.
Statistic Explanation Equation  Equation number
Intraclass 
correlation
Normalized difference of the squared deviations 
between pairs 
MSA = mean-squared deviation among pairs 
MSW = mean-squared deviation between pairs
(𝑀𝑀𝑀𝑀𝑀𝑀 −𝑀𝑀𝑀𝑀𝑀𝑀)(𝑀𝑀𝑀𝑀𝑀𝑀 +𝑀𝑀𝑀𝑀𝑀𝑀) 
 
 
Equation 75 
Concordance, 
pairwise
Conditional probability that both members of 
a twin pair are affected if at least one of the 
members is
𝑁𝑁concordant(𝑁𝑁concordant + 𝑁𝑁discordant) 
  Equation 76
Concordance, 
casewise
Conditional probability that a twin is affected if 
the co-twin is
2𝑁𝑁concordant(2𝑁𝑁concordant + 𝑁𝑁discordant) 
 
 
Equation 77
8.2.4 STATISTICAL mETHODS
Regression (simple, multiple or logistic) is used to determine whether a variable 
or variables predict a variable of interest. At its simplest, the regression equation 
is in the form of a straight line, i.e.
𝑦𝑦 =  𝛼𝛼 + 𝛽𝛽𝛽𝛽 + 𝑒𝑒  (Equation 78)
where y is the dependent variable, x	is	the	independent	variable,	α	is	the	intercept,	
β	is	the	regression	coefficient	and	e is an error term (residuals). In the least-squares 
method,	α	and	β	are	calculated	by	solving	β	by	summing	over	the	squares	of	all	
deviations	of	the	observed	data	from	the	predicted	line	and	finding	α	from:
𝑦𝑦� = 𝛼𝛼 − 𝛽𝛽?̅?𝑥  (Equation 79)
In ordinary least squares, the squared deviations are summed with equal weights. 
In weighted least squares, different weights are assigned to each deviation (e.g. zero 
for outliers). Multiple regression analysis is an extension of the simple regression 
where y is predicted by several independent xi	each	with	unique	βi.
Structural equation modelling and path analysis
Path diagrams are a graphical way to display relations between manifest variables 
(measured	 traits),	 latent	 influencing	 (genetic	 and	 environmental)	 factors,	 the	
“strength” of paths between them as well as the similarity between relatives. They 
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are	used	to	describe	theoretical	structures	(i.e.	models)	and	fit	models	to	real	data	
using an array of statistical approaches. Figure 9 is a typical univariate (one-variable) 
model where a phenotypic trait P of twin pair members P1 and P2 is shown with 
the latent additive (A), dominance (D), shared environmental (C) and unique 
environmental (error) (E) variance components. 
a)
1P
1A 1C 1E
2P
2A 2C 2E1D 2D
1.0 1.0 1.0
a c e a c e
1.0 1.0 1.0
1.0 / 0.5 1.0
1.0
d
1.0
d
1.0 / 0.25
b)
1P
1A 1C 1E
2P
2A 2C 2E1D 2D
AV CV EV
1.0 1.0 1.0 1.0 1.0 1.0
AV CV EV
1.0 / 0.5 1.0
DV
1.0
DV
1.0
1.0 / 0.25
Figure 9. Example of a univariate (one-variable) model with a phenotypic trait P of twin pair members P1 and P2 and with the latent variance components. In panel a) the variances are fixed to 1.0 and the 
path coefficients are calculated. In b) the variance components will be estimated from data (Neale 
2004). With permission from Springer Netherlands.
The covariances between twins 1 and 2 have a value 1.0 for both A and D for 
MZ twins, and 0.5 and 0.25, respectively, for DZ twins. In SEM, the chi-squared 
goodness-of-fit	statistics	are	used	to	assess	how	well	a	model	fits	 the	data.	The	
relative	goodness	of	fit	of	different	models	can	be	tested	using	the	likelihood	ratio	
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test, which is based on the more general model (like AE) being nested in a detailed 
model (for example ADE). Comparing the AE and ADE models gives the following 
likelihood ratio:
LR = 𝜒𝜒2(AE) ±  𝜒𝜒2(ADE)  (Equation 80)
with degrees of freedom:
𝑑𝑑𝑑𝑑 = 𝑑𝑑𝑑𝑑(AE) ± 𝑑𝑑𝑑𝑑(ADE)  (Equation 81)
If the new chi-squared 𝜒𝜒2 ,	thus	obtained,	i.e.	the	likelihood	ratio,	is	significant	at	p 
=	0.05,	this	means	that	there	is	deterioration	in	the	fit	of	the	model	when	the	extra	
variable,	D	in	the	example,	is	fixed	at	zero	(Neale	2004).
8.3 GENETICS OF COmPLEX DISORDERS
As estimation of heritability from twin and family data comes under quantitative 
epidemiology.	 The	 molecular	 genetics	 of	 complex	 disorders	 are	 only	 briefly	
mentioned here.
The major successes in genetics have been for rare monogenic disorders, the 
number of which now exceeds 5,000. In approximately half of these, a mutation 
has	been	identified	(Gilissen	2012).	Most	common	conditions,	 like	diabetes	and	
obesity, are, however, complex and do not follow a single-gene dominant or recessive 
pattern of inheritance (Smith 2003).
Regardless of the mode of inheritance, the basic genetic approach has in outline 
remained the same: identify the trait or disease, decide how to approach its genetic 
variance component, collect biological samples, isolate the DNA, get the phenotype 
information and try to associate a chromosomal region, a gene locus or a causative 
variant for the trait or disease phenotype in question. Some designs used commonly 
only a few years ago are rarely used now, but are described below for the sake of 
completeness.
If a trait seems to follow Mendelian inheritance, the commonest way to explore 
its genetics is to ascertain pedigrees, identify phenotypes and search for a linkage 
between a genetic marker and the affected phenotype. The underlying assumption 
is that affected pedigree members in a generation are identical by descent (IBD): 
they have all inherited the genotype causing the trait from the same ancestor. 
Before recombinant DNA technologies, the only available genetic markers 
were blood groups and human leukocyte (HLA) antigens. In fact, in genetic 
studies blood was collected from family members, centrifuged and the buffy 
coat containing the DNA was discarded (Hinrichs 2011). Today, polymorphic 
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DNA regions are used as markers. Polymorphism implies that the base pair 
variability	is	sufficient	to	segregate	individual	differences.	The	early	markers	were	
restriction fragment polymorphisms (RFLPs), which were followed by simple 
sequence-length polymorphisms (SSLPs) and microsatellites (Gilissen 2012). 
The most commonly used markers today are single-nucleotide polymorphisms 
(SNPs). They are densely present throughout the genome and stable compared 
to microsatellite markers and, because of their binary nature, can be used for 
automated high-throughput genotyping (Sachidanandam 2001). 
Only approximately one-fourth of diseases follow Mendelian inheritance and 
the rest have more or less complex genetics (Jin 2012). According to Lander and 
Schork, “The term complex trait refers to any phenotype that does not exhibit classic 
Mendelian recessive or dominant inheritance attributable to a single gene locus. In 
general, complexities arise when the simple correspondence between genotype and 
phenotype breaks down, either because the same genotype can result in different 
phenotypes (due to the effects of chance, environment, or interactions with other 
genes) or different genotypes can result in the same phenotype” (Lander 1994). An 
interesting additional observation by Jin et al. was that 13% of diseases had both 
Mendelian and complex modes of inheritance and that 54% of the Mendelian genes 
were also associated with complex disorders (Jin 2012). This has also been seen 
for diabetes, where common variants of the genes that cause MODY are associated 
with common type 2 diabetes.
A fundamental reason for the complexity is the nature of disease diagnosis, which 
is very often based on signs and symptoms (as is common in psychiatric conditions), 
extremes of normal physiology (such as diabetes, obesity and hypertension) that 
carry	an	elevated	risk	of	clinical	complications	or	descriptions	of	abnormal	findings	
in medical imaging or organs (many pathology diagnoses). All of these share the 
characteristic that the causal agent or mechanism is rarely known. As disease 
variants	become	identified	for	cases,	those	that	remain	are	“idiopathic	or	essential”	
cases of unknown cause. 
Several	features	complicate	the	identification	of	non-Mendelian	disease	genes.	
These include incomplete penetrance, phenocopies, heterogeneity, polygenic 
inheritance including additive effects and epistatic interactions, high frequency 
alleles and other genetic mechanisms of inheritance. A variety of methods have 
been	used	to	overcome	these	difficulties.	The	affected	sib-pair	method,	originally	
described in 1935 (Penrose 1935), has been widely used, especially for disorders 
with a large gene effect (Suarez 1978). The sib-pair approach has more power when 
there is information not only of affected sibs, who are identical by state (IBS), but 
also of their parents. Weeks and Lange developed the affected pedigree member 
method by substituting IBS relations with information about generalized IBD 
relations (Weeks 1988). 
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Linkage-based studies rely only on information about allele segregation for a trait 
or disease. Association studies ask, on the other hand, whether an allele of a gene 
(related to a protein) assumed to be involved in the disease process, is more prevalent 
among cases than controls. Finding genetically matched cases and controls is often 
challenging in case–control studies. This has led to the use of internal controls, 
like the untransmitted allele of the parents of an affected sib in the transmission 
disequilibrium test (TDT) and haplotype relative risk test (HRR) (Spielman 1996). 
In 1996 Risch and Merikangas showed that an association scan using one million 
genetic variants dispersed throughout the genome would be more powerful than a 
linkage using hundreds of markers (Risch 1996). That became reality ten years later, 
and genome-wide association studies have since 2007 been the main method for 
studying complex diseases. According to the National Institutes of Health, a GWAS 
is	defined	as	“any	study	of	genetic	variation	across	the	entire	human	genome	that	
is designed to identify genetic associations with observable traits (such as blood 
pressure or weight), or the presence or absence of a disease or condition”. In addition, 
to	meet	the	definition	of	a	GWAS,	the	density	of	genetic	markers	and	the	extent	
of	linkage	disequilibrium	should	be	sufficient	to	capture	a	large	proportion	of	the	
common variation in the genome of the population under study, and the number 
of	samples	(in	a	case–control	or	trio	design)	should	provide	sufficient	power	to	
detect variants of modest effect (Anon 2007). 
An	optimal	set-up	for	a	GWAS	includes	well-defined	quantitative	or	dichotomous	
phenotypes, and an ethnically homogeneous study population. These criteria must 
often	be	compromised:	the	trait	is	classified	as	either	present	or	absent	(effected	
versus unaffected), populations must be pooled and the allele frequencies therefore 
corrected	for	population	stratification	(Bush	2012).	
Complex disorder genetics is based upon how genomes at the population level 
change over time. The shorter the distance between two alleles in a chromosome, the 
more likely it is that they are passed together in meiosis, a condition called linkage 
disequilibrium (LD). Linkage disequilibrium measures the fragmentation of the 
genome at the population level. Fragmentation increases generation after generation 
and populations move from LD towards linkage equilibrium (Lange 1993). 
A gene search attempts to identify alleles in LD with disease genes. Alleles, 
including SNPs, segregate as haplotypes, i.e. knowing a “tag” SNP enables 
identification	of	the	rest.	The	International	Haplotype	Map	Project	(HapMap)	was	
set up in 2002 to identify groups of SNPs that are highly correlated (designated as 
having a high r2) throughout the genome for different ethnic populations (Anon 
2005).	According	to	HapMap,	a	sufficient	coverage	(over	80%)	of	the	genome	can	
be attained using 550,000–1,100,000 SNPs with a minor allele frequency (MAF) 
of at least 5% (Frazer 2007). The basis for setting the MAF limit to 5% has been not 
only economical and practical but also theoretical. According to the common disease, 
common variant hypothesis (CDCV), common gene alleles dispersed throughout the 
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genome	are	responsible,	each	via	a	small	effect	and	in	undefined	ways,	for	the	risk	
for common diseases (Lander 1996). The CDCV hypothesis has been challenged as 
it has become clear that Mendelian disease genes are involved in common diseases 
and	that	a	significant	gap	exists	between	population-based	complex	disease	h2 values 
and the observed h2 values based on GWAS (Jin 2012).
The increase in the power and cost-effectiveness of nucleotide research 
techniques	has	occurred	in	parallel	with	the	increasing	number	of	identified	SNPs.	
The development of DNA arrays with 0.5 to 1 million oligonucleotides on a thumb-
sized computer-compatible microchip has enabled real genome-wide association 
studies,	and	the	first	results	came	in	2007	(DiStefano	2011).	By	2013,	more	than	
9,000 GWAS reports had been published, with each year surpassing the previous 
one (Hindorff 2013). 
A major change in methodologies took place in 2008, when laboratories shifted 
from automated Sanger-sequencing techniques to next-generation sequencing 
(NGS) (Metzker 2010). Although comparing results from the different commercial 
NGS platforms is demanding, the speed and unit cost of sequencing have improved 
drastically	over	the	last	five	years.	To	sequence	a	genome	in	2007	cost	approximately	
10 million USD. In 2012 the same procedure cost less than 10,000 USD and the 
aim is to reach 1,000 USD per genome (Wetterstrand 2013). Despite the progress, 
whole genome sequencing (WGS) still is resource intensive and targeted sequencing 
strategies have been favoured. The most common of these is whole exome 
sequencing (WES), which analyses only protein-coding regions. Exomes comprise 
approximately 2% of the human genome and WES costs on average a tenth of what 
is needed for WGS (Myllykangas 2013). In addition, the huge amount of data poses 
huge challenges for bioinformatics and obtaining and storing detailed individual 
genetic information raises ethical questions. However, the main challenge is to 
understand the NGS results. This was formulated by the Human Genome Variation 
Society in a meeting report from 2013: “The ability to create this information has 
been noted, but the ability to understand the effect of a genetic variant on disease, 
or disease predisposition, is still in its infancy” (Ellard 2013).
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9. AIMS OF THE STUDY
1. To study the extent to which insulin action and insulin secretion, as measured 
with gold standard methods, are affected by genetic factors for middle-aged 
twins without diabetes.
2. To estimate the heritability, that is the proportion of the risk for type 2 
diabetes due to genetic factors, by using generation-long follow-up data 
from a population-based twin cohort study.
3. To compare the twin-study based heritability estimates with those obtained 
from a large collection of families with type 2 diabetes mellitus. 
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10. MATERIALS AND METHODS
10.1 STUDy SUBJECTS
10.1.1 THE FINNISH TWIN COHORT STUDy 
The twins participating in the current study comprise the so-called older cohort 
of the Finnish Twin Cohort Study, which is attempting to identify the genetic and 
environmental determinants of chronic diseases and their risk factors (Kaprio 
1978, 2002). A baseline questionnaire was given in 1975 to twin pairs of the same 
gender born before 1958, and the individual response rate was 89%. Twin zygosity 
was determined in 1975 from the responses of the members of each pair to two 
questions on the similarity of their appearance at primary school age. A set of 
decision rules was used to classify 93.1% of the twin pairs as MZ or DZ, while 6.9% 
remained undetermined. A validation study using genetic markers showed that this 
questionnaire method is highly accurate (Sarna 1978). 
10.1.2  THE BOTNIA STUDy
The Botnia Study was originally initiated in 1990 in four primary care centres 
(Narpes, Malax-Korsnas, Korsholm and Jakobstad) in Western Finland near the 
Gulf of Botnia. Swedish and Finnish incomers, whose descendants remained in 
this mixed rural and urban area, settled the region about 1,000 years ago. The 
prevalence of diabetes is about 3%. About 85% of patients have type 2 diabetes 
(Eriksson 1992) and the initial treatment was diet alone or oral anti-diabetic agents 
for at least 6 months. All 1,164 patients with known type 2 diabetes from the centres 
were invited to participate in the study. The response rate was 95% and patients with 
type	2	diabetes	who	had	at	least	two	living	first-degree	family	members	(parents,	
siblings	or	children)	were	selected	for	further	study.	All	first-degree	family	members	
were invited to participate in the study; 76% of them (n = 2,152) were examined 
within	the	first	two	years.	There	was	an	average	of	2.8	persons	in	each	of	the	732	
families. Most of the non-respondents were emigrants living in Sweden or in the 
US. A total of 528 randomly chosen spouses without a family history of diabetes 
served as control subjects. 
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10.1.3  DATA COmPILATION 
Studies I to III
Twin pairs resident in Helsinki and the surrounding communities, with no diabetes 
according to earlier questionnaires, were randomly selected from the Twin Cohort 
and invited to participate in the studies. All subjects underwent an OGTT (plasma 
glucose and serum insulin at 0 and 120 min). Altogether 210 twin pairs were 
identified	and	the	response	rate	was	about	74%.	The	study	protocols	have	been	
reviewed and approved by the local ethics committee. Informed written consent 
was obtained from all subjects before their participation. Some pairs were excluded 
because they were taking anti-diabetic drugs (n = 4) or because of unclear zygosity 
(n	=	1).	The	final	study	sample	consisted	of	151	twin	pairs.	Of	these	302	individuals,	
there were 24 (9 MZ), 54 (23 MZ) and 14 (6 MZ) subjects with impaired fasting 
glycaemia (IFG), impaired glucose tolerance (IGT) and diabetes, respectively, 
following WHO criteria (WHO 1999). Among these, there were 1 DZ pair concordant 
for IFG, 1 MZ and 4 DZ pairs concordant for IGT and a single MZ pair concordant 
for type 2 diabetes.
Study IV
Data on the incidence of type 2 diabetes mellitus in twins between 1976 and 1987 was 
first	collected	through	linking	computerized	records,	using	the	unique	personal	ID	
assigned	to	all	Finns,	from	death	certificates,	the	National	Hospital	Discharge	Register	
and the Medication Register of the Social Insurance Institution. The results were 
published in 1992 (Kaprio 1992). The same information resources were used to gather 
information on new cases of diabetes between 1988 and 1995 for the same cohort of 
twins.	This	data	was	examined	by	two	research	physicians	using	the	same	classification	
of diabetes as in the earlier report, who determined a date for the diagnosis. Finally, 
the Medication Register was used in 2006 to update the information on all medical 
certificates	for	diabetes	between	1996	and	2004	for	the	twin	cohort.	This	compilation	
included	only	a	general	diagnosis	of	diabetes,	birth	date	and	the	date	for	certificate	
admission. As all study subjects were 38 or older in 1996, it was assumed that all of 
them	had	type	2	diabetes	and	that	the	date	of	diagnosis	was	the	date	of	certification.	
Individuals with diabetes in 1975, based upon a questionnaire or from the registers, 
were excluded from the analysis. During a follow-up, the vital status was obtained 
from the Population Register Centre of Finland, including information on deaths, 
migration and the current address in Finland. 
After combining the datasets, there were 32,778 twin individuals (16,507 males 
and 16,271 females) in the cohort. After removing subjects with diabetes at the 
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baseline	or	undefined	zygosity	(mainly	due	to	non-responses	in	the	questionnaire)	
or who had moved abroad or died before 1 January 1976, there were 23,585 twin 
individuals with self-reported BMI available (11,446 men and 12,139 women; 
7,374 MZ and 16,211 DZ). Among them, there were 4,076 MZ and 9,109 DZ pairs, 
respectively. In the analyses, after considering possible confounders, there were 
23,238 twins remaining (11,292 males and 11,946 females; 7,269 MZ and 15,969 DZ), 
as twins with missing covariate data (information on educational level, occupation, 
social class, leisure time physical activity and alcohol consumption) were removed. 
In the calculation of concordances, only pairs with both members with complete 
information available were used (3,327 MZ and 7,182 DZ).
The numbers are summarized in Table 9.
Table 9. Summary of the number of participating twin pairs in studies I to IV.
Numbers of pairs Study I Study II Study III Study IV
IVGTT OGTT IVGTT & OGTT
Number of MZ pairs 
(male/female)
21
(15/6)
21
(15/6)
33
(16/17)
13
(9/4)
66
(28/38)
4,076
(1,911/2,165)
Number of DZ pairs 
(male/female)
20
(13/7)
20
(13/7)
23
(12/11)
14
(9/5)
85
(33/52)
9,109
(4,570/4,539)
Study V
Family information was obtained for 25,962 individuals from 1,131 families 
participating in the Botnia Study. For the heritability estimates of quantitative traits 
and type 2 diabetes, we restricted the analysis to families with phenotype information 
from at least two members, which resulted in 5,810 individuals from 942 families 
with an average family size of 6.16. Of these, 1,707 had type 2 diabetes. Diabetes 
was diagnosed using the WHO 1999 criteria (WHO 1999). Patients with GAD 
antibodies or known MODY mutations were excluded. The clinical and metabolic 
characteristics were recorded for all individuals and non-diabetic individuals 16 
years or older.
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10.2 mETHODS
10.2.1 ANTHROPOmETRIC, BODy COmPOSITION AND BLOOD PRESSURE 
mEASUREmENTS
Height (to the nearest centimetre without shoes) and weight (to the nearest kilogram 
in light indoor clothing) were recorded. The body mass index (BMI) was calculated 
as weight/height2 (kg·m–2). The waist circumference (to the nearest centimetre 
without clothes) was measured with a non-elastic soft tape midway between the 
lowest rib and the iliac crest on standing subjects. The hip circumference (to the 
nearest centimetre without clothes) was measured over the widest part of the gluteal 
region. The waist-to-hip ratio (WHR) was calculated as a measure of abdominal 
obesity. The fat-free mass (FFM) and fat mass (percentage) were measured using 
bioelectrical impedance (Segal 1985, Franssila-Kallunki 1992). In study V, lean body 
mass was estimated by measuring the absorption of infrared light in subcutaneous 
tissue (Futrex, Gaithersburg, MD, USA). Systolic (SBP) and diastolic (DBP) blood 
pressure was measured with a mercury sphygmomanometer (Speidel and Keller, 
Jungingen, Germany) from the right arm of the subjects after a 15-min rest. The 
results were expressed as the mean of three consecutive readings for studies I to IV 
with the patients in a sitting position, and as the mean of two recordings for study 
V with the patients in a supine position.
In study IV, the twins were asked for their current weight (kg) and height (cm), 
which were used to assess their BMI (kg·m–2) at baseline. The validity of the self-
reported BMIs was tested for a subsample of twins (100 men and 125 women) from 
the	same	cohort	by	first	asking	for	their	weight	and	height	in	a	questionnaire	in	1990,	
and	then	measuring	them	in	1992–1993.	The	correlation	coefficients	between	self-
reported and measured BMIs in men and women were 0.89 and 0.90, respectively 
(Korkeila 1998).
10.2.2 ASSESSmENT OF INSULIN SECRETION AND GLUCOSE mETABOLISm
A polyethylene cannula was placed in an antecubital vein of the study subjects after 
an overnight fast and baseline blood samples were drawn to measure fasting plasma 
glucose, serum insulin and plasma C-peptide concentrations. 
OGTT: studies II, III and V
OGTT was used to characterize the glucose tolerance status and to estimate beta 
cell function. Subjects ingested 75 g glucose solution over 5 min. After 120 min, 
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blood samples were drawn to measure plasma glucose, serum insulin, and plasma 
C-peptide (study III) concentrations. A subset of twin pairs underwent OGTT with 
additional blood sampling at 30, 60 and 90 min (study II). For study V, the blood 
samples for plasma glucose and serum insulin concentrations were drawn at –5, 
0, 30, 60 and 120 min.
IVGTT and clamp tests
In the IVGTT and euglycaemic hyperinsulinaemic clamp tests, the blood was 
sampled using a polyethylene cannula inserted retrogradely into a dorsal hand or 
a distal forearm vein. The hand was placed in a heated (70º C) box to arterialize 
the venous blood (Liu 1992).
IVGTT: studies I and II
IVGTT was used to measure insulin secretion: 0.3 g/kg body weight of glucose 
(maximum dose 35 g) was infused intravenously for 2 min and arterialized blood 
samples were drawn at 0, 2, 4, 6, 8,10, 20, 30, 40, 50 and 60 min to measure 
plasma glucose and serum insulin concentrations. 
Clamp tests: studies I and II
The	 whole-body	 glucose	 uptake	 was	 quantified	 with	 a	 160-min	 euglycaemic	
hyperinsulinaemic clamp test (DeFronzo 1979, Eriksson 1989): an intravenous 
primed continuous insulin infusion of 45 mU/min per m2 was administered 
and maintained for 160 min, while euglycaemia was maintained using a variable 
intravenous infusion of 5% glucose. The plasma glucose level was assessed at the 
bedside from samples of arterialized blood drawn every 5 min.
Botnia clamp
IVGTT and clamp testing were carried out on separate days for 14 MZ and 5 DZ twin 
pairs and on the same day for 8 MZ and 15 DZ pairs (Tripathy 2003). When done 
on the same day, the clamp test was started 30 min after the end of the IVGTT. In 
these	subjects,	the	glucose	uptake	was	adjusted	for	the	influence	of	the	preceding	
IVGTT. Overall, a preceding IVGTT resulted in a 7% increase in the glucose uptake 
during the clamp test. Both members of a twin pair participated in the same protocol. 
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10.2.3 LABORATORy ASSAyS
Plasma glucose was measured in duplicate with a glucose oxidase method using a 
Beckman Glucose Analyzer II (Beckman Instruments, Fullerton, CA). Serum insulin 
concentrations in studies I to IV were measured by RIA (Pharmacia, Uppsala, 
Sweden) with an interassay CV of 5%, and in study V by an enzyme immunoassay 
(DAKO, Cambridgeshire, UK) with an interassay CV of 7.5%. Serum C-peptide 
concentrations were measured by RIA with an interassay CV of 9% (Linco, USA). 
10.2.4 CALCULATIONS
Beta cell function
IVGTT: studies I and II 
In	study	I,	the	first-phase	insulin	secretion	(FPI)	was	calculated	as	the	incremental	
area	under	the	 insulin	curve	during	the	first	10	min	and	the	 late-phase	 insulin	
secretion (LPI) was calculated as the incremental area under the insulin curve 
during the last 50 min of the IVGTT. The area under the curve was calculated 
using the trapezoidal rule. In study II, beta cell secretion during IVGTT was 
estimated by applying a model of glucose-induced insulin secretion to the glucose 
and insulin curves of each subject. This model is similar to the one proposed for 
C-peptide during hyperglycaemic clamp testing (Bonadonna 2003), which was 
based primarily on the minimal model for C-peptide during IVGTT (Toffolo 1995). 
It is described in the appendix of study II. Both readily releasable insulin (RRI; 
pmol·l-1)	quantifying	first-phase	insulin	secretion	as	well	as	sigma,	that	is	beta	cell	
sensitivity to glucose during the second phase of insulin secretion ([pmol·l–1·min-1] 
per [mmol·l–1]), were estimated by implementing this model of insulin secretion 
in the commercially available software package SAAM. This package was used to 
create ordinary differential equations from a compartmental model structure, to 
simulate complex experimental protocols for the model, to solve the model and to 
fit	it	to	the	data	(Barrett	1998).
OGTT: studies II, III and V
In study II, beta cell secretion during OGTT was estimated by applying a model 
of glucose-induced insulin secretion to the glucose and C-peptide curves of each 
subject, as previously described by us (Cretti 2001). The model for C-peptide kinetics 
and secretion was resolved with the aid of the SAAM software package, and in 
all studies it was used to calculate the OGTT beta index (log units), a compound 
parameter of beta cell function during OGTT. The parameters for glucose-induced 
beta cell secretion were estimated to good precision, as shown by the CVs for RRI: 
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11.7 ± 0.9%; sigma: 28.8 ± 1.7% and the OGTT beta index: 10.5 ± 1.2%. In study 
V, the beta cell response to oral glucose was assessed using the insulinogenic index 
(Equation 3). In studies III and V, beta cell function was also estimated by calculating 
the HOMA-BETA index (Equation 1).
Insulin sensitivity
Clamp testing: studies I and II
In studies I and II, insulin sensitivity was assessed using the euglycaemic 
hyperinsulinaemic clamp method by calculating the amount of infused glucose 
needed to maintain euglycaemia during the last 40 min of the study (120–160 
min). The insulin sensitivity was expressed as glucose uptake in mg/min per kg of 
weight and per kg of FFM. The latter was used in the calculations. 
Other indices of insulin sensitivity: studies III and V
The homeostasis model index for insulin resistance (HOMA-IR) (Equation 12) was 
used in studies III and V. In study V, the insulin sensitivity index (ISI) was also 
calculated from OGTT as suggested by Matsuda (Equation 14).
10.2.5 STATISTICAL mETHODS
Data are expressed as means ± SD. Trait values were transformed to normality 
as indicated. The data were also analysed separately for female and male twins 
whenever sex-related effects were detected. The clustering of data, since the study 
population consisted of twin pairs, was taken into account in the comparison of 
the MZ and DZ mean values (studies II to IV). Differences between the MZ and 
DZ twin pairs were tested with a two-tailed t test. If not otherwise stated, a p value 
was	considered	significant	if	less	than	0.05.	For	study	V,	asymmetrically	distributed	
variables were log-transformed before analysis, and all quantitative trait analyses 
were adjusted for age, sex, the interaction between age and sex, age2 and affection 
status (type 2 diabetes). In addition, all traits except BMI were adjusted for BMI. 
The	covariates	not	found	to	be	significant	after	covariate	screening	were	removed	
from	the	final	models.
In study IV, the Cox proportional hazard regression was used to estimate the 
relative risk of incident type 2 diabetes mellitus by BMI category (underweight: 
under 18.5 kg·m–2, normal weight: 18.5 to 24.9 kg·m–2, overweight: 25 to 29.9 kg·m–2, 
obese: 30 to 34.9 kg·m–2 and morbidly obese: 35 kg·m–2 and over), by integer values 
of BMI, as well as per unit BMI and per SD of BMI. For type 2 diabetes cases, the 
follow-up ended at the date of diagnosis, while other subjects were censored at the 
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time of death, migration from Finland or end of follow-up (31 December 2004). 
Regression models were adjusted for age and sex only as well as for additional 
covariates.
In	study	V,	sibling	relative	risk	(λS) was calculated as the risk of diabetes in 
siblings of patients with type 2 diabetes compared with the background population, 
following the method proposed by Olson and Cordell (Olson 2000). Differences in 
Pearson	correlation	coefficients	between	parent–son	and	parent–daughter	pairs	
were evaluated using the corcor function (Goldstein 1996), which is a test for 
dependent	correlation	coefficients	in	Stata	(StataCorp	2003).
The statistical packages used are summarized in Table 10.
Twin correlations and variance components in studies I to IV
Standard univariate twin analyses were carried out (Williams 1992), including 
the test for homogeneity of the mean values and variances across the twin type. 
Maximum likelihood analyses based on sample covariance matrices were used to 
estimate the components of variance (Williams 1992, Neale 2004). In a study of 
twins reared together, it is possible to model four separate components: (A) an 
additive genetic component, (D) effects due to dominance and (C) shared and (E) 
non-shared	environmental	components.	One	can	fit	the	models	based	on	different	
combinations of these variables (AE, ACE, ADE and CE) but the effects due to 
dominance and shared environmental effects cannot be simultaneously modelled 
with	data	from	twins	reared	together	(Neale	2004).	Chi-squared	goodness-of-fit	
statistics	were	used	to	assess	how	well	the	model	fitted	the	data.	The	relative	goodness	
of	fit	of	different	models	was	tested	using	the	likelihood	ratio	(Equations	56	and	
57).	The	simplified	alternative	comparison	of	intraclass-correlation	coefficients	for	
MZ and DZ pairs was also used (Equation 50). 
In study II, a cross-twin cross-trait (ctct) correlation (the correlation of trait 1 
values for twin 1 vs. trait 2 values for twin 2, and vice versa) of RRI and sigma was 
also performed, to see if there was a common genetic factor.
Bivariate analyses were performed to study the degree of correlation of the latent 
genetic	and	environmental	factors	influencing	both	Ins_0	and	Ins_120	(study	III)	
and BMI and type 2 diabetes (study IV). In study III, variance components were 
estimated	by	applying	the	maximum	likelihood	method	to	fit	the	models	to	the	raw	
data, using age and sex as covariates. In study IV, age-adjusted bivariate genetic 
factor models were estimated separately for male and female twin pairs, using the 
mean and variance weighted least-squares method (WLSMV) implemented in the 
MPlus software system (Prescott 2004). BMI was included as a continuous trait and 
type 2 diabetes as a dichotomous trait. The bivariate model in study IV yielded, along 
with	the	variance	components,	the	coefficients	for	phenotypic	(r), intraclass (IC) 
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and genetic (rg) correlations and the correlation between environmental variance 
components (re).	The	bias-corrected	95%	confidence	intervals	were	estimated	using	
a bootstrap method with 1,000 draws.
Heritability of type 2 diabetes and quantitative traits in the Botnia Study, 
study V
The SOLAR software package provides a maximum likelihood estimate of 
heritability, taking into account additive genetic effects and residual errors (Almasy 
1998). Heritability is the proportion of the phenotypic variance that is due to additive 
genetic effects after adjustment for covariates. The heritability of type 2 diabetes 
was estimated using a liability threshold model implemented in SOLAR (Duggirala 
1997). In addition to the common covariates (age, sex, age•sex, age•age and BMI), 
the SNP in TCF7L2, rs7903146, was added as a covariate for the analysis of h2 of 
type 2 diabetes.
Table 10. Statistical packages . 
Study Name Purpose Reference
IV MPlus Twin variance component analysis
www.statmodel.com 
Prescott 2004
I, II, III Mx Twin variance component analysis
www.vcu.edu/mx/ 
Neale 2004
II
SAAM
(Simulation, Analysis And 
Modeling)
Compartmental model simulation 
and solving
www.saam.com  
Barrett 1998
V
SOLAR 
(Sequential Oligogenic 
Linkage Analysis Routines)
Genetic variance component 
analysis Almasy 1998
I SOLO Descriptive statistics, phenotypic correlations
www.ncss.com 
Lovie 1989
II, III, 
IV Stata versions 7 & 8
Descriptive statistics, phenotypic 
correlations, hazard ratios
www.stata.com
StataCorp 2003
I,II,III Twinan Twin correlations Williams 1992
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11. RESULTS
Detailed	results	are	given	in	the	original	publications	and	only	briefly	summarized	here.
11.1 CLINICAL CHARACTERISTICS
A summary of the clinical characteristics of twins participating in studies I to IV 
and the individuals in study V are shown in Tables 11 and 12. The twins in studies 
I to III were selected from the cohort for study IV. The age and BMI in study IV 
are from 1975, when the follow-up for that study began. All twins participated in at 
least two studies. The glucose tolerance of the twins was normal in studies I to IV.
Table 11. Clinical characteristics of MZ and DZ twins.
Study I Study II Study III Study IV
Number of MZ pairs  
(female/male)
21  
(6/15)
42  
(20/22)
66  
(38/28)
3,289 
(1,782/1,507)
Number of DZ pairs  
(female/male)
20  
(7/13)
28  
(12/16)
85  
(52/33)
7,090 
(3,639/3,451)
Age MZ (years) 61.4 ± 4.3 63.1 ± 4.9 59.8 ± 0.9 35.8 ± 14.7
Age DZ (years) 63.5 ± 2.3 66.5 ± 3.5 59.0 ± 0.8 35.8 ± 14.1
BMI MZ (kg·m–2) 26.2 ± 3.1 26.8 ± 0.5 26.9 ± 0.4 22.6 ± 3.4
BMI DZ (kg·m–2) 26.5 ± 3.0 26.6 ± 0.4 26.9 ± 0.4 22.9 ± 3.3
WHR MZ male 0.94 ± 0.01 0.947 ± 0.009
WHR DZ male 0.98 ± 0.01 0.959 ± 0.008
WHR MZ female 0.82 ± 0.01 0.837 ± 0.011
WHR DZ female 0.85 ± 0.01 0.839 ± 0.010
Fasting glucose MZ (mmol·l–1) 5.6 ± 0.1 5.6 ± 0.1
Fasting glucose DZ (mmol·l–1) 5.9 ± 0.1 5.7 ± 0.1
Fasting insulin MZ (pmol·l–1) 50 ± 4 8 ± 0
Fasting insulin DZ (pmol·l–1) 48 ± 3 9 ± 0
2-hour glucose OGTT MZ 
(mmol·l–1) 6.8 ± 0.2 6.7 ± 0.2
2-hour glucose OGTT DZ 
(mmol·l–1) 7.7 ± 0.4 6.7 ± 0.2
2-hour insulin OGTT MZ 
(mmol·l–1) 44 ± 4
2-hour insulin OGTT DZ 
(mmol·l–1) 48 ± 4
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The individuals in study V were patients with type 2 diabetes and their family 
members, all of whom are participating in the Botnia Study. There was no overlap 
between them and the populations for studies I to IV. 
The 5,810 individuals in the Botnia Study were from 942 families with an average 
family size of 6.17. The average number of individuals with type 2 diabetes per family 
was 2.28 and the average number of individuals not affected was 5.08. OGTT was 
performed on those patients with type 2 diabetes whose fasting plasma glucose was 
less than 10 mmol·l-1. The average age, BMI, WHR, fasting glucose and insulin, 
2-hour glucose and insulin of individuals with type 2 diabetes were higher and 
insulin sensitivity and acute beta cell stimulatory responses lower than the respective 
values in non-diabetic subjects (Table 12).
Table 12. Clinical characteristics of individuals in study V.
Characteristic All individuals Non-diabetic individuals
n Mean ± SD n Mean ± SD
Male/female 2,691/3,119 1,854/2,168
T2D (%) 1,707 (29.8)
Age (years) 5,810 52.68 ± 17.26 4,022 47.22 ± 15.97
BMI (kg.m-2) 5,655 26.58 ± 4.52 3,978 25.79 ± 4.10
WHR 5,554 0.9 ± 0.09 3,930 0.88 ± 0.09
Fasting glucose (mmol·l-1) 5,744 6.48 ± 2.27 4,008 5.52 ± 0.59
2-hour glucose OGTT (mmol·l-1) 4,865 7.79 ± 4.23 3,806 6.24 ± 1.58
Fasting Insulin (pmol·l-1) 5,371 73 ± 63 3,781 50 ± 35
2-hour Insulin OGTT (pmol·l-1) 4,599 366 ± 337 3,608 328 ± 301
HOMA-R (mmol·mU·l-2) 5,344 3.32 ± 4.08 3,770 2.08 ± 1.35
ISI ((mmol·l)2·(mU·l)2) 4,488 5.56 ± 3.41 3,535 6.24 ± 3.4
HOMA-BETA (%) 5,344 85.89 ± 89.48 3,770 89.63 ± 84.63
IG30 (%) 4,460 21.41 ± 37.59 3,506 24.6 ± 41.44
DI (mmol·mU·l-2) 4,460 53.35 ± 99.54 3,506 54.69 ± 105.85
T2D: Type 2 diabetes mellitus, ISI: Matsuda insulin sensitivity index, IG30: Insulinogenic index 
(OGTT ratio of 30 min incremental increase of insulin and glucose), DI: Disposition index (product 
of HOMA-R and IG30)
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11.2 PHENOTyPIC CORRELATIONS
The phenotypic correlations between variables are given in the original publications 
for studies I to V.
11.3 BmI AND THE RISK OF DEVELOPING TyPE 2 DIABETES 
mELLITUS (STUDy IV)
The phenotypic correlations between BMI and type 2 diabetes was 0.40 in men and 
0.38 in women. The overall HR of type 2 diabetes was 1.22 (95% CI 1.20–1.24) per 
BMI unit and 1.97 (95% CI 1.87–2.08) per 1 SD of BMI (see Figure 2 in the original 
publication for study IV). The risk for diabetes increased monotonously after BMI = 
20 over the entire BMI spectrum. Altogether 1,332 twins (6.3% of males and 5.1% of 
females)	developed	type	2	diabetes	by	the	end	of	the	follow-up,	with	no	significant	
difference associated with zygosity (HR = 0.93 for DZ twin individuals with 95% CI 
of 0.82–1.06). The HR of developing type 2 diabetes increased linearly from 1.00 
among subjects with normal weight, to 6.80 among obese subjects (BMI = 30–35 
kg·m–2), when age, sex, physical activity, alcohol consumption, educational status 
and social class were all used as covariates. In morbidly obese subjects (BMI = 35 
kg·m–2 or more), the risk for type 2 diabetes was twofold, compared with individuals 
classified	as	obese.	
11.4 TWIN CORRELATIONS
An	intraclass	correlation	coefficient,	or	 intraclass	r, measures the similarity of a 
trait between members within a twin pair: a trait value of twin 1 is compared to 
the same trait value of twin 2. Monozygotic twins share all their genes and gene 
combinations, and therefore often display higher intraclass r than DZ twins do. 
Table 13 is a pooled presentation of the intraclass r values from studies I to IV. 
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Table 13. Intraclass correlation coefficients of type 2 diabetes and selected metabolic traits from 
the Finnish Twin Cohort Study.
Pool Studies I and II Study III Study IV
MZ DZ MZ DZ MZ DZ
T2D female 0.63 0.34
T2D male 0.74 0.34
BMI 0.60 0.04 0.63 0.28
BMI female 0.67 0.25 0.71 0.34
BMI male 0.62 0.45 0.71 0.41
WHR female 0.89 -0.13 0.69 0.28
WHR male 0.68 0.08 0.46 0.32
Fasting glucose 0.46 0.24 0.50 0.37
Fasting insulin 0.49 -0.06 0.43 0.15
HOMA-R 0.38 0.04
Glucose uptake 0.46 0.01
FPI 0.55 0.24
LPI 0.66 0.11
RRI 0.78 0.32
Sigma 0.67 0.42
Beta index 0.57 0.23
T2D: Type 2 diabetes mellitus, FPI: IVGTT first-phase insulin secretion, LPI: IVGTT late-phase 
insulin secretion, RR: IVGTT readily releasable insulin secretion, Sigma: IVGTT beta cell sensitivity 
to glucose during the second phase of insulin secretion, Beta index: OGTT compound parameter 
of beta cell function.
The BMI intraclass r values for study IV represent the situation in 1975. For study 
III, they were obtained using a subset of the same twins, almost 20 years later. By 
comparing the ratio of MZ/DZ intraclass r values we can see, that among females, 
the ratio increased from 2.09 to 2.6 whereas among males it decreased from 1.73 
to 1.38. This could indicate that dominance effects increased among women twins 
while	shared	environmental	influences	became	more	important	among	aging	male	
twins. However, as the intraclass r values represent the complete populations in 
studies III and IV, they are not directly comparable.
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11.5 HERITABILITy OF TyPE 2 DIABETES AND ASSOCIATED 
TRAITS
11.5.1 DIRECT ESTImATES OF HERITABILITy
Heritability, h2, is the proportion of trait variance explained by genetic factors. Table 14 
summarizes h2 estimates of the most important traits from all included studies. Also 
shown in the table are h2 values of the non-diabetic study population from study V.
Table 14. Heritability estimates of type 2 diabetes and selected diabetes-related traits from the Finnish 
Twin Cohort Study (studies I to IV) and the Botnia Study (study V).
Studies I and II Study III Study IV Study V
h2 95% CI h2 95% CI h2 95% CI h2 95% CI
T2D, all 0.25 0.15–0.35
T2D, 35–60 
years 0.69 0.38–1.00
T2D, female 0.64 0.52–0.74
T2D, male 0.73 0.64–0.81 
BMI, all 0.54 0.15–0.93 0.68 0.53–0.78 0.46 0.40–0.52
BMI, non-
diabetic 0.53 0.45–0.61
BMI, female 0.75 0.50–1.00 0.71 0.68–0.75
BMI, male 0.61 0.29–0.93 0.75 0.71–0.78
WHR, all 0.27 0.21–0.33
WHR, female 0.76 0.13–1.00 0.73 0.47–0.99
WHR, male 0.70 0.13–1.00 0.48 0.13–0.84
Fasting glucose 0.14 0.00–0.53 0.45 0.27–0.60 0.58 0.50–0.66
Fasting insulin 0.41 0.02–0.80 0.43 0.23–0.59 0.34 0.26–0.42
HOMA-R 0.42 0.22–0.59 0.37 0.29–0.45
Glucose uptake 0.37 0.00–0.82
FPI 0.55 0.20–0.90
LPI 0.58 0.25–0.91
RRI 0.76 0.53–0.88
Sigma 0.28 0.00–0.79
Beta index 0.53 0.26–0.72
IG30 0.50 0.42–0.58
DI 0.46 0.38–0.54
ISI 0.40 0.32–0.48
T2D: Type 2 diabetes mellitus, FPI: IVGTT first-phase insulin secretion, LPI: IVGTT late-phase 
insulin secretion, RR: IVGTT readily releasable insulin secretion, Sigma: IVGTT beta cell sensitivity 
to glucose during the second phase of insulin secretion, Beta index: OGTT compound parameter 
of beta cell function, IG30: Insulinogenic index (OGTT ratio of 30 min incremental increase of 
insulin and glucose), DI: Disposition index (product of HOMA-R and IG30), ISI: Matsuda insulin 
sensitivity index.
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The h2 values have been discussed in each of the original publications. Only some 
of the estimates could be compared between studies. The body mass index was 
measured in all studies and its h2	was	the	most	constant.	The	confidence	intervals	
for h2 for type 2 diabetes did not even overlap when the group 35–60 years, which 
received the highest estimate, was compared with the group for all individuals (study 
V). A summary of h2 estimates of several age groups from study V is separately 
shown in table 15. 
Table 15. Heritability of type 2 diabetes in different age groups in the Botnia Study (study V).
Age group Number of individuals in the age group 
Number (%) of 
individuals with type 2 
diabetes
Heritability estimate 
(SE) using basic 
covariates
All 5,326 1,349 (25.3) 0.25 (0.05)
16–60 years 3,760 718 (19.1) 0.50 (0.12)
16–65 years 4,291 949 (22.1) 0.46 (0.10)
16–75 years 5,070 1,262 (24.9) 0.27 (0.07)
35–60 years 2,746 663 (24.1) 0.69 (0.16)
35–65 years 3,277 894 (27.3) 0.56 (0.12)
35–75 years 4,056 1,207 (29.8) 0.31 (0.09)
Basic covariates used: age, sex, age·sex, age·age and BMI
The h2 for type 2 diabetes among twins in study IV was high among both men 
(0.73) and women (0.64). This was indirectly also demonstrated in the progression 
of	zygosity-specific	relative	risk	of	the	non-diabetic	co-twin	in	pairs	discordant	for	
type 2 diabetes. 
Although studies I to III with small populations were in general characterized 
by	large	confidence	intervals,	traits	used	for	the	quantitation	of	insulin	sensitivity	
(fasting insulin, HOMA-R, clamp glucose uptake and OGTT insulin sensitivity index) 
all had h2 estimates around 0.40, regardless of the study, method and population size.
11.5.2 INDIRECT ESTImATES OF HERITABILITy
The relative risk of a non-affected twin (study III)
Because study III included a follow-up, the time it took for the non-diabetic co-twin 
of an affected twin to develop type 2 diabetes was measured. The MZ concordance 
rates (0.41 proband-wise and 0.34 pairwise) were higher than those among DZ 
twins (0.19 and 0.12). Approximately half of the MZ twins and a third of the DZ 
twins with an affected co-twin developed type 2 diabetes (Figure 3 in the original 
publication for study IV). The mean age at the start of the follow-up, sex or the age 
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at	which	the	first	of	the	twins	in	a	pair	was	diagnosed	with	type	2	diabetes,	were	
not	significant	predictors.
Distribution of quantitative traits across families (study V)
Histograms of Botnia Study family means of the insulinogenic index (IG30) and 
the insulin sensitivity index (ISI) had a symmetric Gaussian distribution (Figure 1 
in the online supplementary material in the original publication for study V). We 
selected the family means and ranges for 20 families from the lower tail (5%) and 
20 families from the upper tail of the trait distributions (Figure 3 in the online 
supplementary material in the original publication for study V). Although both the 
insulinogenic index and ISI showed large intrafamilial variance, their interfamily 
differences were larger.
11.5.3 BIVARIATE ANALySIS
In	study	III,	Ins_0	and	Ins_120	were	influenced	by	a	shared	genetic	factor.	Using	
AE	as	the	final	bivariate	model,	the	genetic	correlation	coefficient	(rg) between the 
latent	polygenetic	factors,	influencing	the	variances	of	both	fasting	and	2-hour	(post-
challenge) insulin values, was estimated to be 0.81 and the correlation between the 
unique	environmental	influences	(re) 0.54.
In study IV, up to 28 years of follow-up of 23,585 twins enabled the calculation 
of rg between BMI and type 2 diabetes mellitus. Using a bivariate AE model, rg was 
estimated to be 0.40 in men and 0.45 in women. To express the result in another 
way, the genetic covariation with BMI explained 16% (men) and 21% (women) of 
the	genetic	covariance	of	type	2	diabetes	mellitus.	The	coefficients	for	re were 0.37 
in men and 0.22 in women.
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12. DISCUSSION
This study is the fruit of two successful activities in Finnish medical research: 
studying type 2 diabetes mellitus and studying twins. 
The Finnish Twin Cohort Study (Kaprio 1978, 1994) is a national resource for 
genetic epidemiological studies. Twins and their families have been ascertained 
in three different times from the Central Population Register to study the genetic 
and environmental determinants of common, chronic diseases. In 1992, this data 
on Finnish twins was used to estimate the cumulative incidence, concordance 
and heritability of type 1 (insulin-dependent) and type 2 (non-insulin-dependent) 
diabetes in Finland (Kaprio 1992). The somewhat unexpected observation, that 
heritability for type 1 diabetes was higher than that for type 2 diabetes, whetted our 
appetite for testing the extent to which insulin sensitivity and insulin secretion were 
controlled for by genetic factors. Methods for studying this were already available 
at the IV Department of Medicine of Helsinki University. Our group there had 
recently	shown	for	the	first	time	that	non-diabetic	family	members	of	individuals	
with type 2 diabetes mellitus were insulin resistant (Eriksson 1989). It was, further, 
no	coincidence	that	the	finding	had	also	inspired	the	Botnia	Study,	which	included	
most families with type 2 diabetes in the Ostrobotnia region of western Finland, in 
a search for the genetic origins of type 2 diabetes (Groop 1996).
These assumptions can be found in the original publications: three publications 
on insulin-mediated glucose metabolism, insulin secretion and glucose tolerance in a 
subsample of the Finnish Twin Cohort Study, a prospective study on the heritability 
of type 2 diabetes using all older cohort twins from the Finnish Twin Cohort Study 
and,	finally,	a	study	on	the	heritability	of	type	2	diabetes	and	related	metabolic	traits	
with all available families from the Botnia Study. 
One strength of the current thesis is the careful delineation of heritability of type 2 
diabetes, insulin sensitivity and insulin secretion. The h2 estimates for glucose uptake 
and	IVGTT-derived	insulin	secretion	were	the	first	to	be	published	(study	I)	and	
have been cited by several authors (Poulsen 2001, Hong 2001, Ashley 2002, Geluk 
2004, Stumvoll 2005, Simonis-Bik 2011, Gjesing 2012). The provided h2 of 0.37 for 
insulin-stimulated glucose uptake has proven to be in accordance with other studies 
using euglycaemic hyperinsulinaemic clamp testing (Goodarzi 2005, Poulsen 2005). 
The	significance	of	h2 obtained using the clamp technique is increased by studies 
showing that the genetic correlation between insulin sensitivity estimated using the 
clamp technique and using HOMA-IR is only moderate (Rasmussen-Torvik 2007).
The timeliest observation from studies I and II has been that the variance of 
insulin secretion, especially the early phase, is mostly accounted for by genetic factors. 
The conclusion that IVGTT early insulin secretion could be used as a quantitative 
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trait,	agrees	with	findings	from	genome-wide	studies,	which	have	highlighted	genes	
associated with insulin secretion rather than with insulin sensitivity. In the NHGRI 
GWAS Catalogue, accessed on 15 June 2013, out of a total of 100 mapped type 2 
diabetes genes, 43 were associated with insulin secretion or the pancreas in general 
and 24 genes with insulin resistance (Hindorff 2009).
With	regard	to	finding	optimal	beta	cell	function	phenotypes	for	genetic	studies,	
two observations from studies I to III deserve mention: (1) genetic factors explained 
up to three-quarters of the variance of early insulin secretion and (2) in OGTT, the 
same set of genes seemed to be responsible for 65% of the additive variance of both 
fasting and 2-hour insulin concentrations. If the early insulin response is the most 
sensitive predictor for the transition from normoglycaemia to impaired glucose 
tolerance (Giannini 2012), a model-based estimate obtained from IVGTT would 
be an optimal phenotyping tool in a search of genes that control beta cell function.
Heritability for type 2 diabetes using all of the Botnia family data was lower than 
using age groups (study V) or when compared to h2 obtained from twin data (study 
IV). The latter estimate can be regarded as the most reliable, as it was based on a 
follow-up	of	28	years.	With	this	in	mind,	the	gender-specific	bivariate-model-based	
h2 for type 2 diabetes of 64% in male twins and 73% in female twins, and of 69% 
in Botnia Study individuals of 35–60 years, seem quite comparable.
The weaknesses of both the design and implementation of the current studies 
have been discussed in the original publications. A principal concern, however, is 
the	use	of	heritability	as	an	instrument	to	measure	the	influence	of	genetic	factors	
on a trait. The question has taken centre stage since it is apparent that despite the 
GWASs	finding	numerous	new	loci	associated	with	complex	traits,	the	combined	
effects of these loci seem only to cover a minor part of the estimated trait’s h2. We, 
for instance, have shown, that at least two-thirds of the variance of the risk for 
type 2 diabetes should be due to genes. That is over six times more than the 10% 
obtained by combining information from all loci in the major GWAS (Voight 2010). 
At present, there is no clear explanation for this “missing heritability” for type 2 
diabetes, or other complex traits (Maher 2008, Manolio 2009). There has been 
considerable	scientific	discussion,	however,	and	some	of	the	perspectives	raised	
are mentioned here. 
1. The h2	estimates	are	inflated.
The preconditions for SEM should be remembered: independency of genetic 
and environmental effects, independency of environmental effects across 
individuals and the joint effect of independent additive small genetic effects. 
Differences	in	shared	environmental	influences	have,	to	some	extent,	been	
shown to exist (Plomin 1976, Eaves 2003, Richardson 2005) between MZ 
and	DZ	twin	pairs.	Epistatic	influences,	like	DNA	methylation	and	differences	
in DNA copy number variants seem to accumulate in MZ twins during 
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their lifetime (Fraga 2005, Bruder 2008). A fundamental feature of studies 
of phenotypic resemblance within pedigrees is the nature of the kinship 
coefficient,	Φij, since heritability estimates are based on a probability-based 
relatedness of the pedigree members. The h2 obtained in this way is high 
compared to the case–control set-up of a GWAS (Visscher 2010).
With these in mind, it is of interest that we, by using (a) a population-
based twin approach with a long follow-up and (b) a proband-based large 
family approach, obtained almost identical h2 values for type 2 diabetes.
2. The GWASs underestimate h2. 
According to Peter Visscher, the observed underestimation of GWAS-based 
heritabilities could be due to a “dilution” of h2 in case–control approaches of 
unrelated individuals (Visscher 2010) as well as to the conceptual features 
of the GWAS approaches in question. The latter includes both the chosen 
SNP mean allele frequency of 5%, which ignores most of the rarer variants, 
and the primary question of whether the common disease, common variant 
idea is relevant at all (Lupski 2011). In 1908 Punnett had to explain why 
recessive genotypes are not removed, and similarly Gabor Marth wrote 
in 2011, based upon the 1000 Genomes Exon Pilot Project, that “variants 
conferring direct changes on protein function will be present mostly at low 
population frequency” (Marth 2011). This would imply that alleles with 
a large effect are cleared from a population during evolution and, hence, 
the expected polygenic variance of common traits would include the input 
from rare variants. Furthermore, this can be interpreted to mean that 
recent	mutations	 in	populations	may	have	a	 larger	 influence	on	disease	
susceptibility, or protection, than older ones, which have been attenuated 
by evolutive forces. Lupski called this “clan genomics” (Lupski 2011).
3. What to do next? 
 A lively discussion has been ongoing for a number of years and possible 
ways to lower the MAF to 1% or below have been proposed. In 2010 Yang 
published an analysis of a GWAS on human height, where all information 
from 300,000 SNPs was used simultaneously and the relatedness between 
study subjects was reconstructed using only this SNP information. As a result, 
the SNP-based h2 was 45% while using the conventional GWAS approach, it 
had been around 5% (Yang 2010). Zuk and Lander proposed recently that in 
addition	to	calculating	the	allelic	status,	a	component	reflecting	the	function	
of the biological processes should be implemented. Using Crohn’s disease as a 
model, by introducing a variable degree of rate-limiting pathway inputs they 
were able to explain 80% of Crohn’s disease’s missing h2 (Zuk 2012). Finally, 
Finnish researchers recently published a study combining metabolomic 
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information from nuclear magnetic resonance (NMR) spectroscopy and 
GWAS data for densely mapped SNPs, and were able to cover 40% of the 
genetic variance component observed among twins from the Finnish Twin 
Cohort study (Kettunen 2012). 
These approaches outline the future directions for the study of h2 values of type 2 
diabetes as well. We have entered an era of systems biology and tools are emerging 
that	for	the	first	time	will	enable	a	fast	exploration	of	the	complete	genome	along	
with a characterization of phenotypes using hundreds of information points 
simultaneously. Combined with the increase in computing power, this may be 
sufficient	to	begin	unravelling	the	stratified	networks	that	constitute	the	genome-
metabolomes associated with type 2 diabetes mellitus. 
This thesis can be seen in the light of the discussion above. It is a compilation 
of Finnish twin and family studies of complex disorders and, as such, represents 
groundwork for projects like the Sequencing Initiative Suomi (SISu), which aims to 
make an almost complete genome variant set available for customized genotyping 
of samples stored in the National Biobank (Palotie 2013).
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13. SUMMARY AND CONCLUSIONS
In this study we have combined information for the older cohort of twins in the 
population-based Finnish Twin Cohort Study with information for individuals 
participating in the Botnia Study, which comprises 1,400 families with type 2 diabetes 
mellitus. Based on the detailed information for the glucose-insulin metabolic axis 
provided by our investigation and the long follow-up of non-diabetic twins and 
the pedigree data of type 2 diabetes and related metabolic traits, the following 
observations can be made:
1. Genetic factors explained much of the risk of getting type 2 diabetes mellitus. 
The heritability, that is the proportion of variance accounted for by genetic 
influences,	of	type	2	diabetes	was	64%	among	female	twins	and	73%	among	
male twins followed for 28 years, and 69% among 35–65-year-old members 
of affected families.
2. The	variance	of	glucose-stimulated	insulin	secretion	included	a	significant	
genetic	component.	For	the	intravenously	stimulated	first	phase	of	insulin	
secretion, the heritability varied, according to the model used, from 58% to 
as high as 76%. The heritability of oral glucose stimulated insulin secretion 
ranged from 46% to 53%.
3. The heritability of insulin-stimulated glucose disposal, that is insulin 
sensitivity, was measured as 37% by hyperinsulinaemic euglycaemic clamp 
testing. Using more surrogate measures, the heritability of insulin sensitivity 
varied between 37% and 42%.
4. Genetic covariation with BMI explained 16% and 21% of the genetic 
covariance of type 2 diabetes mellitus in men and women, respectively.
In conclusion, type 2 diabetes mellitus clusters in families, has a high lifetime 
concordance among MZ twins and results from the complex interplay of genes 
and the environment. The pancreatic secretion of insulin, and especially the early 
phase of the secretion, appears to be that part of the metabolism that encompasses 
the most promising phenotypes for genomic studies of type 2 diabetes.
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